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Abstract
The Wnt/β-catenin signaling pathway is critical to embryonic development and adult
tissue homeostasis. Mutations to Wnt signaling components can cause dysregulation of the
pathway, leading to various human diseases such as cancer. The partially disordered protein
Chibby (Cby) is a conserved nuclear protein that acts as an antagonist in the Wnt/β-catenin
signaling pathway. Cby’s antagonism is accomplished via two mechanisms. First, by
competing with the Tcf/Lef family of transcription factors, Cby abrogates the β-cateninmediated transcription of Wnt signaling genes. Moreover, upon phosphorylation on serine
20 by the kinase Akt, Cby forms a complex with the protein 14-3-3 to facilitate the nuclear
export of β-catenin. Structurally, Cby is composed of an unstructured N-terminal half, while
its C-terminal half harbours a coiled-coil domain. Cby’s N-terminal half comprises a 14-3-3
binding motif, while its C-terminal half mediates the interaction with β-catenin, as well as
TC-1, an antagonist of Cby. In this thesis, the molecular details of Cby’s structural elements
and its interactions with the Wnt signaling components 14-3-3, β-catenin and TC-1 were
investigated. The Cby/14-3-3 interaction was studied by using a combined approach of
nuclear magnetic resonance (NMR) spectroscopy, isothermal titration calorimetry (ITC) and
X-ray crystallography. While the solved crystal structure revealed a canonical 14-3-3
binding mode, NMR spectroscopy and ITC revealed that residues flanking Cby’s 14-3-3
binding motif are involved in the interaction. Next, hydrogen-deuterium exchange mass
spectrometry revealed that in addition to Cby’s disordered N-terminus, Cby contains a
disordered C-terminal extension. ITC and NMR experiments demonstrate that the disordered
N-terminus negatively regulates target binding between TC-1 and Cby’s coiled-coil domain.
Lastly, mutagenesis studies suggest that Cby’s coiled-coil domain utilizes differing binding
modes when interacting with β-catenin and TC-1, with Cby binding as a monomer to βcatenin and as a dimer to TC-1. In conclusion, this thesis demonstrates how Cby’s structural
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elements collectively mediate protein-protein interactions in the Wnt signaling pathway.
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Chapter 1

1

Introduction

1.1 Introduction to Wnt Signaling
Signaling pathways are critical systems utilized across animal life to coordinate
cell-to-cell communication and regulate cellular functions. A cell’s ability to recognize
and respond to signaling molecules in the extracellular environment is crucial for
development, tissue repair, immunity and homeostasis. Strict regulation of these
pathways is critical, as errors from signal transduction can lead to developmental defects
or disease.
The Wnt signaling proteins are involved in multiple developmental events in
embryogenesis including body axis patterning and cell proliferation, and have been
implicated in stem-cell control and adult cell homeostasis [1,2,3]. The Wnt proteins are
part of a family of growth factors that are associated with three downstream pathways:
the Wnt/β-catenin pathway, the Wnt/Ca2+ pathway (reviewed in [4]) and the planar cell
polarity pathway (PCP) [5]. Each pathway has its own set of specific genes that are
targeted upon stimulation [6,7]. Over the past three decades, the most heavily focused
Wnt pathway in this field of study has been the β-catenin-dependent Wnt signaling
pathway, also referred to as canonical Wnt signaling. Here, the transcriptional coactivator β-catenin is a downstream component of the pathway, responsible for the
activation of the pathway’s target genes [8].
A simplified view of canonical Wnt signaling is illustrated in Figure 1.1 A. In
unstimulated conditions (-Wnt signal), cytoplasmic β-catenin exists as part of a large
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protein complex, commonly referred to as the destruction complex, which contains the
scaffolding proteins adenomatous polyposis coli (APC) and Axin [2,9]. β-catenin is
phosphorylated on Ser/Thr residues on its N-terminus by serine/threonine kinases
glycogen synthase kinase 3β (GSK3β) and casein kinase Iα (CK1) [10]. Phosphorylated
β-catenin is subsequently recognized by the F box/WD-repeat β-transducin repeatcontaining protein (β-TrCP) and targeted for ubiquitin-dependent degradation by the
proteasome [11]. Through this mechanism, cytoplasmic β-catenin levels are kept low,
preventing this protein from entering the nucleus. In the nucleus, the T-cell factor (Tcf) /
Lymphoid enhancing factor (Lef) transcription factors, necessary for the expression of
Wnt-specific target genes, interact with the transcriptional repressors Groucho, histone
deacetylase (HDAC) and C-terminal binding protein (CtBP) [12,13].
In the activated Wnt pathway, the Wnt proteins interact with the family of frizzled
(Fz) receptors, which are members of the G-protein coupled receptor family, and the lowdensity lipoprotein receptor-related protein 5/6 (LRP5/6) receptors [14]. The activated
receptors lead to the stabilization and accumulation of β-catenin in the cytosol. β-catenin
that is free from the destruction complex is able to translocate to the nucleus where it
binds to the Tcf/Lef transcription factors to activate Wnt signaling genes [15,16,17].
A defined cellular mechanism by which β-catenin is stabilized has continually
been developed and refined over the past two decades. In a commonly presented model,
the activated receptor complex promotes the recruitment of the cytoplasmic
phosphoprotein Dishevelled (Dvl), a known interactor of Axin. Dvl mediates the
formation of LRP5/6 Wnt signalosomes through its multimerization [18], as well as
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promotes the CK1 phosphorylation of the cytoplasmic domains of LRP5/6. Dvl and the
phosphorylated LRP5/6 collectively recruit Axin to the membrane [19]. The
sequestration of Axin to the cell membrane effectively dissolves the destruction complex,
leading to the stabilization of β-catenin.
The collection of studies that have jointly developed models to describe βcatenin’s stabilization have generally used over-expression strategies to study the
destruction complex. A recent study, conducted by Li et al. [20], which looked at the
endogenous complex, proposed a different model. This study suggests that β-catenin is
not released from the destruction complex upon Wnt signaling. Instead, Wnt signaling
suppresses β-catenin’s ubiquitination by promoting the dissociation of β-TrCP, causing
the destruction complex to be saturated with phosphorylated β-catenin at the membrane.
At this point, any newly synthesized, non-phosphorylated β-catenin is free to translocate
to the nucleus and activate Wnt target genes. This new model is illustrated for
comparison in Figure 1.1 B.
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Figure 1.1 Wnt signaling models
A. A simplified model of the Wnt/β-catenin signaling pathway. In the absence of a Wnt
signal, the destruction complex is intact and β-catenin is targeted for ubiquitination by βTrCP, followed by degradation by the proteasome. Upon activation, Axin is recruited to
the membrane, leading to the dissolution of the destruction complex. Stabilized β-catenin
can then translocate to the nucleus and activate Wnt target genes. B. A new Wnt/βcatenin signaling model based on a study looking at endogenous destruction complex
proteins [20]. Wnt activation recruits the intact destruction complex to the membrane
and blocks the ubiquitination of β-catenin. Any newly synthesized β-catenin proceeds to
activate target genes. Figure was adapted from figures generated by Clevers and Nusse
[3].
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1.2 Wnt/β-catenin signaling in human disease and
therapeutic development
Mutations to proteins involved in Wnt signaling that lead to aberrant activation of
the pathway are frequently observed in human cancers. Germline mutations in the APC
gene lead to a hereditary cancer syndrome called familial adenomatous polyposis (FAP)
[21,22]. These patients carry heterozygous APC mutations, with the second allele
frequently lost in individual cells during adulthood, leading to colon adenomas (polyps)
[23]. Global-exome sequencing projects have shown that the majority of colorectal
cancers carry inactivating APC mutations [24]. The loss of APC function causes
stabilization of cytosolic β-catenin, where it can then constitutively interact with Tcf/Lef.
In some rare cases of colorectal cancer where no APC mutations exist, Axin2 is mutated
[25], or activating point mutations to the regulatory Ser/Thr residues of β-catenin’s Nterminus are discovered [26].
Mutations to Wnt pathway components are not limited to colorectal cancers. For
example, oncogenic β-catenin mutations have been observed in hepatocellular
carcinomas, melanoma, Wilms tumour and liver, endometrial ovarian and prostate
cancers (reviewed in [27]). Outside of cancer, the Wnt signaling pathway has been linked
to type II diabetes, with the identification of specific single nucleotide polymorphisms
(SNPs) to the Wnt proteins WNT5B [28], and WNT10B [29] as well as TCF7L2 [30].
Moreover, aberrant Wnt signaling has been implicated in bone-density syndromes [31] as
well as in Alzheimer’s disease [32].
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With an expanding association to various human diseases, modulation or
disruption of Wnt signaling through the discovery of small molecules has received
extensive research efforts [33]. Presently, the frizzled and LRP receptors that bind to
Wnt proteins have proven to be difficult to target pharmacologically as no effective
small-molecule inhibitors currently exist. However, the development of a biologic agent,
a humanized antibody to the frizzled receptor named Vantictumab, has entered several
clinical trials (https://clinicaltrials.gov/ct2/results?term=omp18R5&Search=Search).
Small molecule screening for Wnt signaling modulators has yielded some success when
targeting upstream components. For instance, Axin stability is regulated by its poly-ADP
ribosylation, a process catalyzed by the enzyme tankyrase [34]. Inhibition of tankyrase
by molecules like IWR [35] and XAV939 [34] lead to elevated Axin levels which then
destabilizes β-catenin. Next, small-molecule inhibitors of the enzyme Porcupine
represent one of the most specific Wnt signaling disruptors discovered to date [35].
Porcupine mediates the attachment of palmitoleate, a 16-carbon monounsaturated fatty
acid, to the Wnt proteins [36]. Wnt proteins that lack lipids are not secreted and as such,
inactive Porcupine cannot produce active Wnt proteins. A compound named IWP2 [35]
has been shown to inactivate Porcupine with high selectivity and has been effectively
used in cell culture experiments to knock down Wnt signaling [37].
The most attractive drug target of canonical Wnt signaling is the Tcf/Lef and βcatenin complex as it operates downstream of the pathway. However, disruption of the βcatenin/Tcf or Lef complex may have undesired consequences; outside of Wnt signaling,
β-catenin is a central component of adhesion junctions. Here, β-catenin links cadherins at
the plasma membrane to α-catenin [38,39]. As Tcfs and Lefs share a common binding
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site with E-cadherin [40], inhibitors that dislodge the β-catenin/Tcf or Lef complex may
disrupt cell adhesions as well.
Dislodging the β-catenin/Tcf or Lef complex by small molecules is a significant
challenge, as the binding interface between these transcription factors and β-catenin
extends over a large surface of β-catenin (Tcf, for example, buries over ~ 4800 Å of
surface area [41]). While a few compounds have been suggested to disrupt complex
formation, such as 2,4-diamino-quinazolines [42] or the molecules PKF115-854 and
CGP049090 (screened by Lepourcelet et al. [43]), their specificity and efficacy have not
been reported.

1.3

Regulation of β-catenin in Wnt signaling

Multiple regulatory strategies employed by the cell focus on various stages of the
Wnt pathway; from the cell membrane to the nucleus. Not surprisingly, β-catenin is a
focal point. Many proteins are found to direct its subcellular localization or impede its
transcription of target genes. First, several regulatory mechanisms are in place to control
the nuclear import and export of β-catenin. For instance, the forkhead box M1 (FoxM1)
transcription factor, whose cellular levels are elevated by Wnt induction, efficiently
promotes the nuclear localization of β-catenin (which it interacts directly with) through
its functional nuclear localization signal (NLS) [44]. Another example comes from the
work of Wu et al. [45], which demonstrated that the activation of Rac1/JNK2 is
fundamental to the Wnt-mediated nuclear localization of β-catenin. This study reveals
that Wnt stimulation increases Rac1 activation, followed by JNK2 activation. JNK2 then
phosphorylates β-catenin on residues Ser191 and Ser605, which promotes β-catenin’s
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nuclear localization. Last, in addition to playing roles in the destruction complex, both
Axin and APC harbour a NLS and NES (nuclear export signal), enabling them to shuttle
in and out of the nucleus along with bound β-catenin [46,47,48].
Several proteins that antagonize the β-catenin/Tcf or Lef complex as a means of
modulating Wnt signaling have been reported. These proteins include inhibitor of βcatenin and Tcf4 (ICAT) [49], the chromatin remodeling enzymes HDAC1 and HDAC2
[50], the transcriptional repressor Kaiso [51] and the cell cycle regulator p15RS [52].
Interestingly, the protein Chibby (Cby), first reported for its role in Wnt signaling by
Takemaru et al. [53], represses β-catenin-mediated expression of Wnt target genes by the
two mechanisms discussed above; it competes with the Tcf/Lef transcription factors for
binding to β-catenin [53], and regulates β-catenin’s nuclear translocation in conjunction
with the 14-3-3 proteins [54,55].

1.4

The Wnt signaling antagonist Chibby

Cby is a 126-residue, 14.5 kDa protein that is evolutionarily conserved from human
to fly (Figure 1.2). Structurally, the protein’s N-terminal half (residues 1-63) is
intrinsically disordered [56] while its C-terminal half (residues 64-126) harbors a coiledcoil domain that promotes the protein’s dimerization [56,57]. The two structural halves
of Cby work together to perform Cby’s function as an antagonist to the Wnt pathway.
First, pulldown assays have demonstrated that Cby’s C-terminal half alone is sufficient
for binding to β-catenin [53]. Meanwhile, Cby phosphorylation at residue serine 20 by
the kinase Akt promotes Cby’s interaction with the scaffolding protein 14-3-3 [54]. This
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Figure 1.2 Cby Multiple Sequence Alignment
Multiple sequence alignment of Cby from human, mouse (Mus musculus), bovine
(Bos Taurus), frog (Xenopus tropicalis), zebrafish (Danio rerio) and fly (Drosophila
melanogaster). Alignment was generated using T-Coffee [58] and figure was made using
BoxShade. Sequence features are labeled.
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Cby/14-3-3 interaction promotes the nuclear exclusion of β-catenin and thus represses the
transcriptional coactivator’s activity [54,55].
A study by Li et al. [55] demonstrated that Cby actively shuttles between the nucleus
and cytoplasm via its NLS and NES. Cby’s NLS is found at its very C-terminus
(residues 123-126) and mediates binding with isoforms of the importin-α family, which
are nuclear transport proteins. Cby’s NES is found within its N-terminal half (residues
21-29) and interacts with nuclear export transporter chromosomal maintenance 1
(CRM1). Cby’s nuclear-cytoplasmic shuttling affects the subcellular distribution and
signaling activity of β-catenin; immunofluorescence microscopy experiments [55] reveal
that deletion of Cby’s NLS leads to cytoplasmic sequestration of β-catenin while loss-offunction mutations to Cby’s NES lead to nuclear retention of β-catenin. TOPFLASH
assays (a Tcf/Lef reporter kit used to measure Wnt signaling activity in cultured cells)
were used to demonstrate that mutations to Cby’s NLS effectively repressed β-catenin
signaling by trapping β-catenin in the cytoplasm. Conversely, mutations to the NES
caused Cby to have markedly reduced ability to antagonize β-catenin signaling,
presumably due to their failure in translocating β-catenin to the cytoplasm.
The protein 14-3-3 stimulates the cytoplasmic sequestration of both Cby and βcatenin through an unclear mechanism. However, the study by Li et al. [55] provides
some evidence that the 14-3-3/Cby interaction promotes Cby’s binding to CRM1 in the
nucleus and inhibits Cby’s interaction with importin-α in the cytoplasm. 14-3-3 may
accomplish repressed β-catenin mediated signaling if it promotes Cby’s export from the
nucleus and prevents its import while Cby is in a β-catenin bound state.
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Cby itself is regulated by a small protein named thyroid cancer 1 (TC-1) [59].
TC-1 binds to Cby in competition with β-catenin, effectively abrogating Cby’s
antagonism. Downstream gene analysis by Jung et al. [59] showed that TC-1 up-regulates
β-catenin target genes such as LAMC2, MMP-7, MMP-14, c-Met, c-Myc and cyclin D1.
Cby’s function in the Wnt pathway suggests that it may be a tumour suppressor
gene. However, very few studies have linked Cby to cancer. Some studies have shown
that Cby is downregulated in colon carcinoma [60] and pediatric ependymomas [61] cell
lines. Xu et al. [62] showed that Cby is highly downregulated in laryngeal squamous cell
carcinoma (LSCC) tissues, however, no correlation between Cby expression and
pathological features of LSCC were observed.
An overview of Cby’s nucleo-cytoplasmic transport and its role in Wnt signaling
is displayed in Figure 1.3 below. Cby plays a crucial role in the Wnt/β-catenin pathway,
yet the understanding of the structural mechanisms it utilizes to interact with its binding
targets is still in need of investigation. The following sections will explore the known
structural information on Cby and its Wnt signaling binding partners β-catenin, 14-3-3
and TC-1.
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Figure 1.3 Cby in Wnt Signaling
Cby’s nucleo-cytoplasmic shuttling is mediated by the transport proteins importin-α and
CRM1. In Wnt signaling, Cby directly competes with the Tcf/Lef transcription factors
for binding to β-catenin. The protein TC-1 alleviates this antagonism. Upon
phosphorylation by Akt, Cby interacts with 14-3-3. CRM1 then translocates Cby and
bound β-catenin out of the nucleus.
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1.5

Structural features and characterization of Cby

Circular dichroism (CD) and NMR spectroscopies demonstrate that Cby’s N-terminal
half (residues 1-64) is intrinsically disordered [56]. Disordered regions within proteins
exist as an ensemble of structures, allowing them to form specific, but commonly lowaffinity interactions with their targets [63]. Their plasticity makes them well suited in
signaling pathways, as the need for reversible binding and interaction with multiple
partners is often necessary [64]. Cby’s N-terminus comprises the protein’s 14-3-3 and
CRM1 binding motifs [54,55].
Analysis of Cby’s sequence across species revealed the presence of a conserved
coiled-coil motif along its C-terminal half [53]. Coiled-coils are common structural
motifs, and typically consist of 2-5 α-helices wrapped around each other into a supercoil
structure [65]. The simple structural design of coiled-coils makes them versatile folding
motifs. They enable proteins to self-oligomerize, hetero-dimerize with compatible coiledcoil domains on other proteins, or mediate interactions with proteins and DNA [66].
Additionally, depending on their function, a coiled-coil may be highly thermostable, or
may require volatility for dynamic folding or binding processes [66]. Coiled-coils are
stabilized by the effective burial of hydrophobic side chains in the core of the supercoil.
These motifs consist of a heptad repeat that follows a pattern of hydrophobic and
charged/polar amino acids.
A classic example of a coiled-coil motif is the basic-region leucine zipper [67].
They are found in many transcription factors, including c-fos and c-jun [68,69]. The
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zipper mediates dimerization of these transcription factors, which is necessary for them to
bind to their DNA binding elements. Heptad repeats are commonly illustrated with
helical wheel representations. The seven positions of each repeat are commonly labeled
a, b, c, d, e, f, g with positions a and d being hydrophobic residues and e and g
predominantly charged/polar [70]. The leucine zippers are so named as leucines are
predominantly found at position d of their heptad repeats.
The first evidence of Cby’s self-association came from a yeast-two-hybrid
experiment that used Cby as bait and ultimately pulled itself out [71]. Gel filtration and
cross-linking experiments by Mofunanya et al. [57] demonstrated that Cby exists
predominantly as a homodimer. The coiled-coil domain of human Cby is displayed in
helical wheel format with four consecutive heptad repeats (residues 73-100) in Figure
1.4. Within the heptad repeats of the coiled-coil, there are four conserved leucines (L77,
L84, L91 and L98) at position d in the helical wheel. Additionally, the coiled-coil
contains two conserved asparagines (N81 and N88), which are buried in the hydrophobic
core (position a). For dimeric coiled-coils, asparagine is commonly found at this position
to promote parallel assembly of the coiled-coil. The parallel assembly is the result of
self-complementary hydrogen bonding of the two asparagines’ side-chains [72].
The dimerization of Cby has been shown to have functional significance in the
Wnt signaling pathway. Alanine mutations to the core leucine residues were previously
shown to disrupt the coiled-coil and monomerize the protein [57]. While these
monomeric mutants maintained the ability to bind to β-catenin and repress β-catenin
mediated signaling, monomeric Cby was incapable of binding to importin-α, thus
disrupting its nuclear import [57].
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Figure 1.4 Cby's coiled-coil domain
Helical wheel diagrams for the predicted Cby coiled-coil domain (residues 73-100). Four
heptad repeats, starting at position g (Glu 73), are displayed as parallel and homodimeric.
Potential interfacial electrostatic bridges are drawn as broken blue lines. Model was
generated using DrawCoil 1.0 (http://www.grigoryanlab.org/drawcoil/).
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Biophysical studies of recombinantly expressed Cby are hindered by its
insolubility [56]. Cby forms inclusion bodies upon expression in E. coli and must be
purified using urea to denature the protein, followed by a refolding procedure. Cby, with
a predicted pI of 9.1, must be refolded in a low pH (pH 5) and low ionic strength buffer.
This restrictive buffer requirement hinders the ability to conduct binding studies between
Cby and its binding targets. As the protein cannot be crystallized, due to its mostly
disordered structure and insolubility, NMR spectroscopy is an attractive method for the
structural characterization of this protein. However, the coiled-coil domain of Cby
suffers from severe line-broadening; only peaks corresponding to Cby’s N-terminus are
observable in Cby’s 1H-15N HSQC spectrum. Deuteration of the protein by expressing
the protein in M9 salts with 100% D2O does not render these peaks observable. The lack
of observable resonances for residues within the coiled-coil domain may be the result of
monomer-dimer exchange, tumbling time of the coiled-coil, or intramolecular
conformational exchange [56].

1.6 Structure of β-catenin and modes of interaction with
Wnt signaling components
Structurally, the 781-residue human β-catenin consists of a central scaffolding
region (amino acids 141-664) made up of 12 armadillo repeats (R1-R12) which are
flanked by intrinsically disordered N- and C-terminal domains (NTD and CTD) [73]
(Figure 1.5 A). Between R12 and the CTD is a conserved helix, termed helix-C,
comprised of residues 667-683 [74]. The armadillo repeats, named after the historical
name for β-catenin in Drosophila [75], are comprised of ~ 42 residues which form three
helices arranged in a triangular fashion [73]. The 12 armadillo repeats collectively form
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an elongated superhelix that harbors a large, positively charged groove that functions as a
binding site for many of β-catenin’s binding partners including Tcf [76], Lef [77], Axin
[78], APC [79], E-cadherin [40] and ICAT [80]. Figure 1.5 B and C illustrate crystal
structures of β-catenin in complex with these Wnt signaling partners. Many of these βcatenin interacting partners share overlapping binding regions and cannot bind β-catenin
simultaneously [81,82]. As such, spatial segregation of these signaling components could
be critical to their function, or competition may be necessary for the regulation of Wnt
signaling.
Tcf/Lef transcription factors all bind similarly to β-catenin [77], with their Nterminal region binding in an extended state along armadillo repeats R5-R10 and a Cterminal α-helix that interacts with repeats R2-R5. Axin binds to the third and fourth
armadillo repeats of β-catenin as a continuous helix [78]. APC contains multiple βcatenin interaction motifs, which include three 15 amino acid (aa) repeats and seven 20aa repeats. Crystal structures revealed that the 15-aa and 20-aa repeats bound to R5-R8 of
β-catenin. Intriguingly, upon phosphorylation of the 20- aa repeats, a downstream region
of APC adopts the ability to interact with R1-R5 of β-catenin, effectively enabling the
phosphorylated protein to outcompete Axin for binding to β-catenin [83]. The antagonist
ICAT is composed of an N-terminal 3-helix bundle and a disordered C-terminus. The 3helix bundle is anchored within repeats R10-R12 of β-catenin while the disordered Cterminus binds along repeats R5-R9, where it can displace Tcf/Lef [80].
The majority of cellular β-catenin participates in adherens junctions, interacting
with cadherins [84]. The cytoplasmic domain of E-cadherin interacts with armadillo
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Figure 1.5 Structure of β-catenin and its binding partners
A. Schematic of the major structural domains β-catenin. B. Cartoon ribbon crystal
structure of β-catenin (PDB: 3OUW, green) in complex with the structurally aligned
proteins Lef-1 (3OUW, red), Tcf-4 (1JPW, blue), Axin (1QZ7, grey), APC (1JPP, cyan)
and E-cadherin (1I7X, orange). C. Structural alignment of Lef-1, Tcf-4, Axin and APC
protein without the visual hindrance of β-catenin and the armadillo repeats they bind to.
D. ICAT in complex with β-catenin (1LUJ). β-catenin from 1LUJ was superimposed
onto a β-catenin molecule from a solved structure where helix C is observed (2Z6H).
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repeats R5-R9. Additionally, upon phosphorylation, a disordered region in E-cadherin
interacts extensively with repeats R3-R4 [40]. A shared binding site between cadherins
and Tcf/Lef makes targeting β-catenin therapeutically very challenging.
Pull-down experiments using truncated β-catenin constructs revealed that the
helix C is critical to the protein’s interaction with Cby, as Cby was observed to bind
markedly weaker to a β-catenin construct comprising of only the armadillo repeat region
[74]. However, detailed structural characterization of the Cby/β-catenin complex has
been mired by the buffer incompatibility of the two proteins. Additionally, NMR
spectroscopy represents a challenging avenue to study this complex due to the severe line
broadening experienced in Cby’s C-terminal half, as well as β-catenin’s large size (~ 88
kDa) and elongated shape.

1.7 Structure, function and binding modes of 14-3-3
proteins
Members of the 14-3-3 family are abundant, ~ 30 kDa acidic proteins found
across all eukaryotic organisms [85]. These proteins were first discovered in 1967, and
are named after the nomenclature used by the researchers Moore and Perez [86] in their
systematic classification of proteins found in bovine brain tissue. Using DEAE-cellulose
chromatography and starch-gel electrophoresis, the 14-3-3 proteins eluted in their 14th
fraction of bovine homogenate and migrated to position 3.3 on their starch gels. In
mammals, there are seven heavily conserved isoforms of 14-3-3 (β, γ, ε, ζ, η, θ, σ) [87]
(Figure 1.6 A). These family members are able to form homo- or hetero-dimers, with
differing levels of preference [88]. For example, the σ isoform preferentially forms
homo-dimers [89] while ε prefers forming hetero-dimers [90]. 14-3-3 dimers interact
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with hundreds of protein targets, including tumour suppressors, kinases, transcription
factors, apoptotic factors and cytoskeletal proteins [91]. With so many binding partners,
14-3-3 plays critical roles in cellular function such as signaling, cell cycle progression,
intracellular trafficking, transcription and apoptosis [87]. Studies have demonstrated that
14-3-3 is directly involved in cellular processes that drive tumour development [92] and
form protein complexes found in neurodegenerative diseases including Creutzfeldt-Jacob
disease (CJD), Parkinson’s and Huntington’s disease [93].
The crystal structures of all 14-3-3 isoforms have been solved and share an
identical fold [88]. The 14-3-3 proteins are nearly entirely α-helical, consisting of nine αhelices (numbered αA-αI) tightly arranged to form a horseshoe like structure (Figure 1.6
A). A positively charged, concave groove comprised of helices αC, αE, αG and αI,
serves as the binding interface for 14-3-3 ligands. Since 14-3-3 proteins are dimeric,
each monomer may scaffold two separate ligands. These ligands may be the same
protein or two distinct ligands. Such a scenario could allow 14-3-3 to juxtapose two
molecules against each other, allowing for molecular communication between the two
ligands. Alternatively, proteins with multiple 14-3-3 binding sites, such as PKCε, may
bind to both 14-3-3 monomers simultaneously, increasing the affinity of the interaction
through avidity [94]. Sequence analysis of 14-3-3 binding partners reveals two major
binding motifs named mode I (RXX[pS/pT]XP) and mode II (RXXX[pS/pT]XP), where
pS and pT represents phosphorylated serine and threonine respectively [95,96]. In crystal
structures of solved 14-3-3 complexes, the phosphorylated serine residue is anchored in
14-3-3’s binding groove by predominantly positively charged residues (in the human ζ
isoform, they are K49, R56, R127 and Y128). Notably, not all 14-3-3 phosphorylated
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binding targets conform to these modes [97] and some do not require phosphorylation at
all [98].
Bioinformatic analysis of 14-3-3 binding sites indicates that they are frequently
found within disordered regions of proteins [99]. The plasticity of these disordered
regions may facilitate the diffusive search for the 14-3-3 binding groove. While 14-3-3
binding motifs make up the core contacts in 14-3-3 complexes, secondary contacts by
residues out of the 14-3-3 motif may also interact with regions outside of the 14-3-3
binding groove. For instance, the only full-length binding partner to have been
successfully co-crystallized to 14-3-3, the 14-3-3/Serotonin N-acetyltransferase complex
[100], displays such secondary contacts, while secondary contacts have also been
demonstrated in 14-3-3 interactions with integrin tails [101]. As the 14-3-3 binding
groove is heavily conserved amongst all isoforms, the presence of these secondary
contacts may direct which isoforms bind to a particular target. Such is the case with the
phosphatase Cdc25, which binds to all 14-3-3 isoforms except the σ isoform [102].
Cby’s 14-3-3 binding motif (RKSApSLS), located within its disordered Nterminus, most closely resembles the mode II motif, with the main exception being a
serine as opposed to a proline at the +2 position relative to the phosphoserine [54]. Coimmunoprecipitation experiments revealed that Cby binds to at least three 14-3-3
isoforms; ε, η and σ [54]. However, whether Cby can interact with the other isoforms of
the 14-3-3 family, or if it preferentially binds particular isoforms is unknown. While the
importance of the Cby/14-3-3 interaction in Wnt signaling has been demonstrated, the
structural details of the complex are not clear.
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Figure 1.6 14-3-3 Sequence, Structure and its Canonical Binding Mode
A. Sequence alignment of the seven human 14-3-3 isoforms generated using T-Coffee
and illustrated using BoxShade. B. Cartoon representation of dimeric structure of 14-3-3
(PDB: 1QJA) in complex with synthetic phosphorylated peptides. C. The phosphorylated
serine residue of the synthetic peptide (pS) making polar contacts (black dotted lines)
with 14-3-3 residues K49, R56, R127 and Y128.
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1.8

The Cby antagonist TC-1

The Cby antagonist and binding partner TC-1 was identified as a gene overexpressed
in papillary thyroid cancer [103]. It enhances β-catenin signaling by relieving the
suppression induced by Cby [59]. Its expression has been correlated with aggressive
behavior in lung and gastric cancers, potentially through activation of the Wnt pathway
[104,105].
Structurally, the 106 residues of TC-1 contain no known functional domains. CD and
NMR spectroscopy experiments demonstrate that the protein is intrinsically disordered
[106,107]. However, secondary structure propensity (SSP) scores, calculated using the
Cα and Cβ chemical shifts, and backbone relaxation experiments reveal three regions
(D44-R53, K58-A64, and D73-T88) in the C-terminal half of the protein with α-helical
propensity [106] (Figure 1.7).
Pull-down experiments by Jung et al. [59] showed that the C-terminal half of TC-1
(residues 51-106) maintained the ability to interact with Cby while the N-terminal half
(residues 1-60) could not. This observation was confirmed by NMR binding
experiments, in which TC-1’s Cby binding site was mapped to the three regions with αhelical propensity [106].
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Figure 1.7 Previous TC-1 NMR Studies
NMR spectroscopy reveals TC-1 is intrinsically disordered and contains three regions
with α-helical propensity. A. 1H-15N HSQC of 15-N labeled TC-1. B. SSP scores for TC1 residues. Regions with α-helical propensity are labeled. This figure has been adapted
from figures generated in [106].
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1.9

Scope of thesis

The partially disordered protein Cby is an antagonist of the Wnt/β-catenin pathway.
Cby’s repression of β-catenin signaling is accomplished by two mechanisms: it competes
with the Tcf/Lef transcription factors for binding to β-catenin, and facilitates β-catenin
export from the nucleus. The Cby mediated nuclear export of β-catenin is dependent on
Cby’s interaction with the adaptor protein 14-3-3. 14-3-3 can form a tripartite complex
with Cby and β-catenin (Figure 1.8), and the formation of this complex is thought to
enable β-catenin’s nuclear export. The protein TC-1 abates Cby’s antagonism through
competitive binding for Cby. In this thesis, the structural details of Cby’s interactions
with the Wnt signaling proteins 14-3-3, β-catenin and TC-1 were investigated.
In Chapter 2, the 14-3-3/Cby complex was structurally characterized. Using X-ray
crystallography, the structure of the complex was solved. A canonical binding mode
between the two proteins was revealed. NMR spectroscopy and isothermal titration
calorimetry experiments reveal that residues flanking Cby’s 14-3-3 binding motif
contribute to the interaction.
NMR studies on Cby have been hindered due to severe line broadening from
residues within its C-terminal half. To structurally analyze Cby’s coiled-coil domain,
hydrogen-deuterium exchange mass spectrometry (HDX-MS) was used. HDX-MS data
revealed that Cby’s C-terminal ~25 residues are disordered, providing evidence for an
additional structural element along with its disordered N-terminus and coiled-coil domain
(Chapter 3). Several Cby constructs that comprise various combinations of Cby’s
structural elements were generated and their interactions with the protein TC-1 were
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studied. It was discovered that Cby’s C-terminal half alone (disordered N-terminus
removed) binds to TC-1 as a dimer and with significantly greater affinity than the fulllength protein, demonstrating that Cby’s disordered regions regulate its target
recognition.
A major challenge in structurally characterizing the Cby/β-catenin complex is
buffer incompatibility. Additionally, the severe line broadening experienced by Cby’s Cterminal half, as well as the large elongated shape of β-catenin, represent significant
obstacles for studying the complex using NMR spectroscopy. In Chapter 4, alanine
substitutions within the core of Cby’s coiled-coil proved effective in disrupting coiledcoil formation and in the process increased the solubility of Cby and lead to the
appearance of C-terminal peaks in HSQC spectra of mutant Cby proteins. Importantly,
the mutants retained the ability to interact with β-catenin in an NMR titration experiment,
suggesting Cby may bind to β-catenin as a monomer. Conversely, these mutants failed to
interact with TC-1, providing additional evidence that Cby binds to TC-1 as a dimer.
Using a variety of biophysical techniques, the work presented in this thesis
provides valuable structural insights into how Cby employs its disordered regions and
coiled-coil domain to interact with Wnt signaling binding partners.
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Figure 1.8 The Cby/14-3-3/β-catenin Tripartite Complex
Schematic of Cby binding to 14‐3‐3 (PDB: 1QJA) and β-catenin (PDB:2Z6H).Cby
utilizes its C‐terminus to bind to the helix C of β‐catenin and its phosphorylated (S20)
N‐terminus binds to 14‐3‐3.
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Chapter 2

2

Structural Analysis of the 14-3-3ζ/Chibby Interaction
Involved in Wnt/β-catenin Signaling

2.1 Introduction
Chibby (Cby) is a small (14.5 kDa), highly conserved protein that functions as a
Wnt/β-catenin signaling antagonist [1]. While the Wnt pathway plays crucial roles in cell
proliferation and differentiation, embryonic development and tissue homeostasis, its
dysregulation contributes to the pathogenesis of an array of human disorders, including
cancer [2,3]. Because of this, pharmacological modulation of the pathway has great
therapeutic potential for disease treatments [4,5,6,7].
Activation of the Wnt pathway promotes the stabilization of the transcriptional
co-activator β-catenin within the cytoplasm, allowing it to translocate to the nucleus and
bind to Tcf/Lef (T cell factor/lymphoid enhancer factor) transcription factors to activate
Wnt target genes [8,9,10,11]. Multiple regulatory strategies employed by the cell focus
on various stages of the Wnt pathway [12], with β-catenin being a focal point. Cby is
one such regulatory protein, suppressing β-catenin-mediated signaling via two distinct
molecular mechanisms. First, in the nucleus, it competes with the Tcf/Lef transcription
factors for binding to β-catenin [1]. Secondly, Cby facilitates β-catenin export from the
nucleus in conjunction with the proteins 14-3-3 and the nuclear export receptor
chromosomal region maintenance 1 (CRM1) [13,14]. In this mode of regulation, Cby
forms a stable trimolecular complex with 14-3-3 and β-catenin [13]. Interestingly,
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binding of 14-3-3 to Cby also leads to an enhanced interaction between Cby and CRM1,
promoting nuclear exclusion of Cby-bound β-catenin [14].
The ability of the 126-residue human Cby to function as a scaffold protein likely
arises from its partially disordered nature. It is well documented that intrinsically
disordered proteins bind to multiple targets by adopting different conformations or via
linear motifs located at different regions in the proteins [15,16,17]. Previous work has
shown that Cby consists of an unstructured N-terminus and contains a coiled-coil motif
within its C-terminus (residues 73-100) that enables dimerization [18,19]. Cby uses its
C-terminus to bind to β-catenin [1], although residues critical for this interaction have yet
to be elucidated. 14-3-3 recognizes the motif 16RKSA(pS)LS22 located in the disordered
N-terminus of Cby, when the serine 20 residue is phosphorylated by the kinase Akt [13].
In this manner, N- and C-terminal binding modules on Cby work together to facilitate the
nuclear export of β-catenin; however, how Cby forms such complexes from a structural
standpoint remains unknown. Our work here focuses on elucidating the binding mode
between Cby and 14-3-3.
The 14-3-3 proteins, which consist of seven isoforms in mammals (β, ɛ, η, γ, θ, ζ
and σ), function as adaptor molecules and are involved in a large range of cellular
processes, including apoptosis, DNA damage response and transcriptional regulation
[20]. Structurally, the ~30 kDa 14-3-3 proteins assemble into homo- or heterodimers,
with each monomer composed of nine anti-parallel alpha-helices (αA-αI) [21]. An
amphipathic groove composed of helices αC, αE, αG, and αI comprise the ligandbinding interface. Generally, 14-3-3 isoforms recognize three consensus binding motifs:
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RXX(pS/pT)XP (mode I), RXXX(pS/pT)XP (mode II) and (pS/pT)X1-‐2-‐COOH (mode
III) where pS/pT represents phosphorylated serine/threonine [22,23]. However, there are
several 14-3-3 binding partners that deviate significantly from these canonical motifs,
including examples of non-phosphorylated partners [24,25].
With hundreds of binding partners discovered to date [26], the 14-3-3 proteins are
classified as signaling hub proteins. Interestingly, many well-structured hub proteins are
found to preferentially bind to unstructured proteins [15]. In fact, the vast majority of 143-3 binding motifs are either found or predicted to be within disordered regions [27,28].
While this is due in large part to the phospho-dependence of 14-3-3 interactions, as
kinases predominantly target unstructured regions for phosphorylation [29], the structural
plasticity of 14-3-3 binding motifs and their neighbouring residues allows 14-3-3 proteins
to target many different proteins with high specificity.
14-3-3 targets are hypothesized to bind to 14-3-3 via primary and secondary
interactions (discussed by Yang et al. [21]). The primary interactions are made between
the 14-3-3 binding motif (including the pS/pT residue) of the target and a conserved
binding groove in the 14-3-3 protein. Secondary interactions occur when residues
flanking the target’s 14-3-3 binding-motif contact regions outside of the conserved 14-33 binding groove. While various crystal structures of 14-3-3 complexes have been
solved, the majority of them have been co-crystallized with short peptides. Observable
electron density is typically only present for 4-10 residues flanking the phosphorylated
residue of the target peptide. While this provides a structural basis for the primary
contacts of the interaction, information regarding the secondary contacts is limited. To
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date, only one (nearly) full-length, globular partner has been co-crystallized with 14-3-3
[30].
The disordered Cby is able to interact with at least three of the seven 14-3-3
isoforms (ɛ, η and ζ) [13], however, whether it can bind to the β, θ, γ, or η isoforms is
unknown. Its 14-3-3 binding motif (16RKSA(pS)LS22) closely resembles the mode II
motif (RXXX(pS/pT)XP), the difference being that Cby contains a serine instead of
proline at the +2 position from the phosphoserine. It is noteworthy that even though
proline is found to be the +2 residue in ~ 50% of known 14-3-3 binding motifs, serine is
in fact the second most commonly found amino acid at that position [25]. To our
knowledge, no 14-3-3/phosphopeptide structure with serine as the +2 residue has been
determined to date.
In this work, the crystal structure of 14-3-3ζ in complex with an 18-residue
phosphorylated Cby-derived peptide was solved to reveal the primary binding
interactions. Secondary interactions between 14-3-3 and the Cby peptide were further
investigated by using nuclear magnetic resonance (NMR) spectroscopy and isothermal
titration calorimetry (ITC). By combining the X-ray and NMR techniques, we were able
to obtain additional molecular details of the binding interface of Cby on 14-3-3.
Additionally, Cby was shown to interact with all seven human isoforms of 14-3-3.
Notably, the backbone assignment of 14-3-3ζ completed in this work will also facilitate
mapping of regions on the 14-3-3ζ surface that are involved in binding other targets.
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2.2
2.2.1

Materials and Methods
Expression and Purification of 14-3-3ζ

The human 14-3-3ζ and 14-3-3σ ORFs were purchased from GeneCopoeia and
were each transferred into a Gateway® pDEST17 vector (Invitrogen). The 14-3-3ζ∆C12,
where the 12 C-terminal residues were deleted, was then generated from the full-length
construct using the QuikChange II Site-Directed Mutagenesis Kit (Strategene). The
constructs for human 14-3-3 β, ε, γ, η, and θ were kindly gifted by the Structural
Genomics Consortium. All 14-3-3 proteins used in this work had their DNA constructs
sequenced. 14-3-3 proteins were expressed as His-tagged protein in Escherichia coli (E.
coli) BL21 (DE3) (14-3-3 β, ε, γ, η, and θ) or E. coli BL21 pLysS (14-3-3ζ, 14-3-3ζ∆C12
and 14-3-3σ) in M9 medium. For unlabeled protein, protein expression was induced at an
O.D.600 of 0.9 by adding 0.75 mM IPTG at 18 ºC for 24 h. The 15N, 13C, 2H labeled 14-33ζ∆C12 was produced by growing E. coli in deuterated M9 medium. Cells adapted to
70% D2O were used to inoculate a 1 L culture of M9 prepared in 100% D2O. Cells were
grown at 37 °C and overexpression was induced at an O.D.600 of 0.6 with 0.75 mM IPTG.
After a 60-h induction at 18 °C, the cells were harvested. All 14-3-3 constructs used in
this study were purified from the crude lysate by affinity chromatography using Ni
Sepharose™ Fast Flow beads (Amersham Biosciences). The tag was then cleaved by
overnight incubation with His-tagged tobacco etch virus (TEV) protease at 25ºC. The
cleaved 14-3-3 was purified from TEV by passing the mixture through Ni Sepharose™
Fast Flow beads. The final yields for the 14-3-3ζ proteins were ~50 mg per L of M9
media (including deuterated media). All 14-3-3 proteins were analyzed on SDS-PAGE
for purity and analyzed for correct mass using electrospray ionization mass spectrometry.
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2.2.2

Peptide Synthesis
The Cby peptides used in this study were purchased from GenScript USA Inc. and

the Tufts University Core Facility. From GenScript USA Inc.: Cby 13-mer (NH212

KTPPRKSASLSNL24-COOH), Cby S20D 13-mer (NH2-12KTPPRKSADLSNL24-

COOH), Cby S20E 13-mer (NH2-12KTPPRKSAELSNL24-COOH), pCby 13-mer (NH212

KTPPRKSApSLSNL24-COOH) and pCby 18-mer (NH2-

12

KTPPRKSApSLSNLHSLDR29-COOH). From Tufts: pCby 7-mer (Ac-

16

RKSApSLS22-NH2), pCby 11-mer (NH2-12KTPPRKSApSLS22-NH2), pCby S22P 7-mer

(Ac-16RKSApSLP22-NH2), pCby S22P 13-mer (NH2-12KTPPRKSApSLPNL24-COOH)
and pCby S22P 18-mer (NH2-12KTPPRKSApSLSNLHSLDR29-COOH). Peptides were
dissolved and dialyzed in 50 mM sodium phosphate, 100 mM NaCl at pH 6.8 for ITC and
NMR experiments.

2.2.3

Crystallization and Structure Determination

Crystals grew within 2 months at 4ºC in sitting drops containing 1 µL of complexed
14-3-3ζ (10 mg/mL) and phosphorylated Cby 18-mer peptide (protein:peptide molar ratio
1:4) in 20 mM Tris, pH 7.5, and 100 mM NaCl and 1 µL of reservoir solution containing
200 mM NH4HCO2 and 16-20% PEG 3350. The mother liquor with 15% glycerol served
as the cryoprotectant for flash-cooling in liquid nitrogen. Data were collected at the
Macromolecular Crystallographic Facility (University of Western Ontario). The structure
was solved via rigid body molecular replacement, using Protein Data Bank entry 1QJA
(14-3-3ζ in complex with mode II peptide) [31] as the starting model. The Cby peptide
was built manually using Coot [32] and refinement was carried out using PHENIX [33].
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2.2.4

NMR Experiments
All NMR experiments were performed using 15N, 13C, 2H-labeled protein samples

in 50 mM sodium phosphate, 100 mM NaCl at pH 6.8. Samples contained 10% D2O and
1 mM 2,2-dimethyl-2-sila-pentane-5-sulfonic acid (DSS) as 1H chemical shift reference.
NMR experiments for the backbone resonance assignment of 14-3-3ζ∆C12 were
conducted at 25 °C on a Bruker Avance 800 MHz (National University of Singapore)
spectrometer equipped with cryogenic probe. Sequential assignments were obtained
from 1H-15N TROSY HSQC, HNCACB, HN(CO)CACB and 15N-NOESY-HSQC
spectra. Data were processed using NMRPipe [34] and analyzed using CARA [35].
For the NMR titrations, either phosphorylated Cby 7-mer or 18-mer peptides were
titrated into 600 µL of ~ 200 µM 15N, 13C, 2H labeled 14-3-3ζ∆C12 until a 3:1 (peptide:
14-3-3ζ∆C12) molar ratio was reached. A 1H-15N HSQC spectrum was collected for
each titration point for a total of 12 points for the pCby WT 7-mer and 18-mer and 6
points for the pCby S22P 18-mer. All spectra were analyzed using NMRView [36].

2.2.5

Isothermal Titration Calorimetry (ITC) Experiments
ITC experiments were performed on a VP-ITC instrument (MicroCal) at 25 °C.

The protein and peptide samples were dialyzed into a buffer containing 50 mM sodium
phosphate, 100 mM NaCl, 1 mM DTT at pH 6.8 and degassed before the experiments.
For ITC experiments testing the binding of the Cby 18-mer to all 14-3-3 isoforms, as well
as the 14-3-3ζ S184E and 14-3-3σ S186E mutants, the buffer used comprised 20 mM
MES, 100 mM NaCl, pH 6.5. In a typical experiment, 5 µL aliquots of ~1-2 mM peptide
were titrated stepwise into the 1.4 mL sample cell containing ~100-200 µM 14-3-3. The
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association constant (Ka), molar binding stoichiometry (n) and the binding enthalpy (∆H),
entropy (∆S) and Gibbs free energy (∆G) were determined by fitting the binding isotherm
to a one-site model with MicroCal Origin7 software. All ITC experiments were
performed in duplicate. Peptide and protein concentrations were determined from amino
acid analysis (Amino Acid Analysis Facility, SickKids, Toronto, ON).

2.2.6

Accession Numbers
The atomic coordinates for the 14-3-3ζ/Cby complex have been deposited in the

Protein Data Bank under accession number 4WRQ. The 1H, 15N and 13Cα/β chemical
shifts of the backbone resonances have been deposited in the BioMagResBank
(http://www.bmrb.wisc.edu), under BMRB accession number 25231.
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2.3
2.3.1

Results
Phosphorylation of serine 20 on Cby is critical for its binding
to 14-3-3ζ

A previous study by Li et al. [13] showed that S20 of Cby is essential for its
interaction with 14-3-3, with the binding being regulated by the phosphorylation of this
serine residue. To quantitatively assess the importance of the phosphorylation of S20 to
the complex formation with 14-3-3ζ, we have used ITC to measure the affinities of a Cby
peptide (12KTPPRKSASLSNL24) encompassing the 14-3-3 binding motif, in both its nonphosphorylated and phosphorylated forms, to 14-3-3ζ. The same peptides containing the
phospho-mimetic mutants S20D and S20E were also included in this study. Our data
show that only the phosphorylated Cby peptide was able to interact with 14-3-3ζ (KD ~
15 µM, Table 2.1 and 2.2), while the other three peptides display no observable binding
(Figure 2.1). Importantly, the phospho-mimetic mutations were unable to rescue the
binding, indicating that the Cby/14-3-3ζ association is driven by the phosphate group on
S20.

Figure 2.1 ITC thermograms with unphosphorylated Cby peptides
ITC thermograms for titrations of unphosphorylated or phospho-mimetic Cby peptides to
14-3-3ζ. A. Cby WT 13-mer. B. Cby S20D 13-mer. C. Cby S20E 13-mer.
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2.3.2

Flanking residues of the consensus 14-3-3 binding motif play
important roles in the Cby/14-3-3ζ association
Next, we assessed the contributions of residues flanking the consensus 14-3-3

binding motif of Cby to the interaction with 14-3-3ζ. The results of our ITC
measurements show that a 7-mer Cby peptide (16RKSA(pS)LS22) comprising the minimal
14-3-3 binding motif bound to 14-3-3ζ with a KD of ~44 µM (Table 2.1 and 2.2, Figure
2.2). Interestingly, phosphopeptides of increasing length exhibit a systematic increase in
binding affinity to 14-3-3ζ (the results are summarized in Tables 2.1 and 2.2 and the
thermograms are shown in Figure 2.2). First, a Cby 11-mer peptide which contains 4
additional residues (12KTPP15) than the Cby 7-mer peptide (16RKSA(pS)LS22) bound with
more than two-fold greater affinity than the Cby 7-mer, with a KD of ~18 µM. A Cby 13mer, with a 2 residue C-terminal extension to the 11-mer (23NL24), bound with only
slightly higher affinity, with a KD of ~15 µM. Lastly, an 18-mer, which contains a fiveresidue C-terminal extension to the 13-mer (25HSLDR29), bound with nine-fold greater
affinity compared to the 7-mer, with a KD of ~5 µM. The results clearly indicate that
residues flanking the binding-motif on Cby play significant roles in mediating the
interaction with 14-3-3ζ.
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Table 2.1 Thermodynamic parameters of binding of phosphorylated Cby peptides to
14-3-3
Thermodynamic parameters for the binding of phosphorylated Cby peptides to 14-3-3. A
duplicate set of experimental values for all ITC experiments is reported in Table 2.2.
Peptide
In ITC Cell: 14-3-3 ζ
WT Cby
Cby 7-mer
16
RKSA(pS)LS22
Cby 11-mer
12
KTPPRKSA(pS)LS22
Cby 13-mer
12
KTPPRKSA(pS)LSNL24
Cby 18-mer
12
KTPPRKSA(pS)LSNLHSLDR29
Cby Mutants
Cby 7-mer S22P
16
RKSA(pS)LP22
Cby 13-mer S22P
12
KTPPRKSA(pS)LPNL24
Cby 18-mer S22P
12
KTPPRKSA(pS)LPNLHSLDR29
Cby 18-mer L24A
12
KTPPRKSA(pS)LSNAHSLDR29
In ITC Cell: 14-3-3 ζ K49A
Cby 18-mer WT
12
KTPPRKSA(pS)LSNLHSLDR29
Cby 18-mer S22P
12
KTPPRKSA(pS)LPNLHSLDR29
In ITC Cell: 14-3-3 ζ Δ C12
Cby 13-mer
12
KTPPRKSA(pS)LSNL24
Cby 18-mer
12
KTPPRKSA(pS)LSNLHSLDR29
a

na

K db
(10-6 M)

∆Hb
(kcal/mol)

T∆Sb
(kcal/mol)

∆Gb
(kcal/mol)

1.01

43.5 ± 1.9

-3.35 ± 0.06

2.60

-5.95 ± 0.03

0.95

17.5 ± 0.6

-3.26 ± 0.02

3.23

-6.49 ± 0.02

1.00

14.5 ± 0.6

-2.63 ± 0.02

3.97

-6.60 ± 0.02

0.96

4.6 ± 0.2

-4.35 ± 0.05

2.93

-7.28 ± 0.03

1.03

2.9 ± 0.05

-6.16 ± 0.01

1.39

-7.55 ± 0.01

1.06

1.1 ± 0.03

-4.64 ± 0.01

3.49

-8.13 ± 0.02

1.05

0.36 ± 0.01

-8.03 ± 0.02

0.76

-8.79 ± 0.02

0.99

21.3 ± 1.7

-1.56 ± 0.05

4.81

-6.37 ± 0.05

1.01

3.8 ± 0.3

-4.16 ± 0.05

3.23

-7.39 ± 0.05

1.07

1.9 ± 0.2

-7.13 ± 0.03

0.67

-7.80 ± 0.06

0.99

14.9 ± 0.9

-2.08 ± 0.03

4.50

-6.58 ± 0.04

1.04

6.8 ± 0.4

-3.35 ± 0.06

3.70

-7.05 ± 0.03

Binding stoichiometry of monomeric 14-3-3 and Cby peptide.
Kd is the dissociation constant ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs
free energy upon binding at T=298.15 K, respectively.
b
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Table 2.2 Duplicate set of thermodynamic parameters for the binding of
phosphorylated Cby peptides to 14-3-3ζ
Peptide
In ITC Cell: 14-3-3 ζ
WT Cby
Cby 7-mer
16
RKSA(pS)LS22
Cby 11-mer
12
KTPPRKSA(pS)LS22
Cby 13-mer
12
KTPPRKSA(pS)LSNL24
Cby 18-mer
12
KTPPRKSA(pS)LSNLHSLDR29
Cby Mutants
Cby 7-mer S22P
16
RKSA(pS)LP22
Cby 13-mer S22P
12
KTPPRKSA(pS)LPNL24
Cby 18-mer S22P
12
KTPPRKSA(pS)LPHSLDR29
Cby 18-mer L24A
12
KTPPRKSA(pS)LSNAHSLDR29
In ITC Cell: 14-3-3 ζ K49A
Cby 18-mer WT
12
KTPPRKSA(pS)LSNLHSLDR29
Cby 18-mer S22P
12
KTPPRKSA(pS)LPHSLDR29
In ITC Cell: 14-3-3 ζ Δ C12
Cby 13-mer
12
KTPPRKSA(pS)LSNL24
Cby 18-mer
12
KTPPRKSA(pS)LSNLHSLDR29
a

na

K db
(10-6 M)

∆Hb
(kcal/mol)

T∆Sb
(kcal/mol)

∆Gb
(kcal/mol)

0.94

47.6 ± 1.6

-3.70 ± 0.04

2.20

-5.90 ± 0.02

0.96

17.5 ± 0.6

-3.27 ± 0.02

3.22

-6.49 ± 0.02

1.07

12.8 ± 0.5

-2.60 ± 0.03

4.07

-6.67 ± 0.02

0.94

4.9 ± 0.3

-4.33 ± 0.06

2.91

-7.24 ± 0.04

1.02

3.2 ± 0.1

-6.21 ± 0.02

1.29

-7.50 ± 0.02

1.02

1.3 ± 0.04

-4.70 ± 0.01

3.33

-8.03 ± 0.02

1.08

0.38 ± 0.01

-7.97 ± 0.01

0.79

-8.76 ± 0.02

1.05

25.0 ± 2.5

-1.37 ± 0.05

4.91

-6.28 ± 0.06

1.07

5.5 ± 0.6

-3.76 ± 0.07

3.41

-7.17 ± 0.06

0.97

1.8 ± 0.1

-6.67 ± 0.04

1.17

-7.84 ± 0.03

1.06

14.5 ± 0.6

-2.08 ± 0.03

4.52

-6.60 ± 0.02

1.02

8.5 ± 0.5

-3.15 ± 0.04

3.77

-6.92 ± 0.03

Binding stoichiometry of monomeric 14-3-3 and Cby peptide.
Kd is the dissociation constant. ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs
free energy upon binding at T=298.15 K, respectively.
b
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Figure 2.2 ITC thermograms for various phosphorylated WT and mutant Cby
peptides titrated into 14-3-3ζ
A. Cby 7-mer. B. Cby 11-mer. C. Cby 13-mer. D. Cby 18-mer. E. Cby S22P 7-mer F.
Cby S22P 13-mer. G. Cby S22P 18-mer. H. Cby L24A 18-mer.
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2.3.3

Molecular basis of the interaction between 14-3-3ζ and the
non-canonical mode II binding-motif of Cby

We used X-ray crystallography to elucidate the molecular basis of the 14-3-3ζ/Cby
interaction. Purified 14-3-3ζ protein was co-crystallized with the phosphorylated Cby
18-mer (12KTPPRKSA(pS)LSNLHSLDR29) and diffraction data were collected to a
resolution of 2.41 Å (Table 2.3). The 14-3-3ζ protein, which crystallized as the typical
cup-shaped dimer [20], has the Cby peptide bound in an extended conformation to each
14-3-3 monomer (Figure 2.3 A). The dimer comprises the asymmetric unit of the crystal,
and the visible electron density was slightly more extensive for the peptide bound to the
B-chain of the dimer. Thus, of the 18 residues in the Cby peptide, eight residues,
18

SA(pS)LSNLH25, were resolved in the peptide bound to the 14-3-3 B-chain (Figure 2.3

B) and seven residues, 18SA(pS)LSNL24, for that bound to the 14-3-3 A-chain (not
shown). Both bound peptides adopted similar conformations and made the same
interactions with the 14-3-3 protein. The lack of observable electron density for the
remaining residues suggests that they remain flexible within the complex.
The overall structural features of the 14-3-3ζ/Cby complex are similar to that of
other 14-3-3ζ/phosphopeptide complexes. The Cby peptide occupies the conserved
binding groove of 14-3-3 with the same orientation as other phosphopeptides previously
characterized. The hydrogen bonding potential of the phosphate group on pS20 is fully
realized, with two hydrogen bonds made to each of R56 and R127, and another hydrogen
bond to the side-chain hydroxyl of Y128 (Figure 2.3 C); 3 water molecules and the side
chain of Cby-S22 mediate four additional hydrogen bonds to the phosphate oxygens.
Thus, each of the phosphate oxygens has 3 hydrogen bonding partners positioned in an
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Table 2.3 Crystallographic data collection and refinement statistics
Values in parentheses refer to the highest resolution shell.
Data Collection
Wavelength (Å)
1.54179
Cell Parameters
a, b, c (Å)
70.83, 71.96, 130.99
Space group
P212121
Resolution (Å)
65.49 – 2.41 (2.53-2.41)
Total reflections
139,670 (16,075)
Unique reflections
26,474 (3445)
0.072 (0.516)
Rmerge
Completeness (%)
98.4 (89.5)
Multiplicity
5.3 (4.7)
I/σ(I)
13.9 (3.2)
Refinement
Rwork/Rfree (%)
RMSD from ideal values
Bonds (Å)
Angles (°)
Overall mean B values (Å2)
Protein
Peptide
Solvent
Number of amino acid residues per
asymmetric unit
Number of water molecules
Ramachandran plot
Favoured regions (%)
Allowed regions (%)
Disallowed regions (%)
Cβ deviations greater than 0.25 Å

0.203/0.256
0.008
1.12
21.71
26.69
19.22
464
147
98
1.8
0.2
0
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Figure 2.3 Crystal structure of the 14-3-3ζ/Cby 18-mer complex
A. Crystal structure of the 14-3-3ζ /Cby 18-mer complex. Each 14-3-3ζ monomer
(coloured orange and blue) is bound to one Cby phosphopeptide. B. Final 2Fo − Fc
electron density of 14-3-3ζ (blue mesh) and Cby 18-mer (green mesh) contoured to 1σ.
C. Polar contacts (black hashed lines) between 14-3-3ζ residues (light blue sticks) and the
Cby 18-mer (green sticks).
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ideal tetrahedral arrangement, explaining why mutation of S20 to D or E fails to promote
high affinity binding of Cby to 14-3-3ζ. The peptide is further coordinated by hydrogen
bonds between the carboxamide of 14-3-3ζ-N224 with the backbone nitrogen and
carbonyl of Cby-A19, the carboxamide of 14-3-3ζ-N173 to the backbone nitrogen of
Cby-L21, and the side-chain of either E180 (chain-C) or W228 (chain-D) of 14-3-3ζ to
the hydroxyl group on the side-chain of Cby-S18. Intra-chain contacts exist within the
Cby peptide as well. On chain-D of the model, consisting of residues 18SA(pS)LSNLH25,
the pS20 amide is hydrogen bonded to the N23 side-chain, the phosphate group itself on
S20 hydrogen bonds with the hydroxyl group on the S22 side-chain, the pS20 carboxyl
contacts both the amide and the side-chain of N23 and the carboxyl of L21 contacts the
amide of L24.

2.3.4

An S22P mutation to Cby enhances its interaction to 14-3-3ζ

As mentioned, Cby comprises a serine (S22) in the +2 position to the
phosphoserine, as opposed to the canonical proline. A comparison between the 14-33ζ/Cby structure with other 14-3-3ζ/phosphopeptide complexes with different +2 residues
[including the canonical proline (Raf1), aspartate (PKCε [37]), glycine (Histone H3 [38]),
threonine (β2 integrin [39]) and leucine (α4 integrin [40])], reveals that the S22 side
chain is oriented uniquely, projecting between 14-3-3ζ residues R56 and K49 (Figure
2.4). Also, superimposition of these peptides onto Cby demonstrates that the backbones
of residues -2 to +1 typically align well but diverge quickly C-terminally from the +2
residue.
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Figure 2.4 Structural comparison of 14-3-3ζ-bound Cby with other 14-3-3 binding
motifs comprising various +2 residues
Residues K49 and R56 are coloured yellow on the white surface representation of 14-33ζ. Structural and sequence alignment of Cby (green sticks) with the binding-motifs of A.
Raf1 (pink sticks, PDB: 3CU8), B. PKCε (orange sticks, PDB: 2WH0), C. Histone H3
(white sticks, PDB: 2C1N), D. β2 integrin (blue sticks, PDB: 2V7D) and E. α4 integrin
(purple sticks. PDB: 4HKC). The Cα RMSD values were computed by subtracting a Cα
distance matrix between the -2 and +1 residues of Cby and each peptide as well as the -2
and most C-terminal residue in the respective alignments.
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With the side chain on Cby-S22 distinctively positioned relative to other +2
residues in 14-3-3/phosphopeptide structures, we sought to determine if mutating this
serine to the canonical proline would have a significant effect on Cby’s interaction with
14-3-3ζ. The same 7-mer, 13-mer and 18-mer Cby phosphopeptides used previously, but
now containing the S22P mutation, were used in ITC experiments to determine the
binding affinity to 14-3-3ζ (Table 2.1, Figure 2.2). Interestingly, for all S22P Cby
peptides, the binding affinity was approximately 15-fold tighter for each peptide
respective to its wild-type counterpart (for 7-mer, KD ~3 versus ~44 µM; for 13-mer, KD
~1 versus ~15 µM; for 18-mer, KD ~360 nM versus ~5 µM). The increases in binding
affinity for the three S22P mutant peptides were all due to more negative ΔH of binding.
Moreover, the flanking residues within the S22P Cby peptides, like the WT, appear to
play a role in the interaction as well. The Cby S22P 18-mer bound ~9 fold tighter than
the S22P 7-mer, similar to the difference observed between the WT Cby 18-mer and 7mer peptides.
In numerous crystal structures of 14-3-3 proteins in complex with phosphorylated
S/T peptides, the conserved K49 (numbering refers to the ζ isoform) side-chain is
observed forming a hydrogen bond with the phosphate group on pS/pT (illustrated in
Figure 2.5 with an elucidated 14-3-3ζ/Raf1 structure). With Cby’s S22 side-chain
juxtaposed between 14-3-3ζ residues K49 and R56, the K49 side-chain is sterically
hindered from contacting pS20. As such, we speculated that the increases in binding
affinity to 14-3-3ζ observed for the S22P mutant peptides might be the result of the
favorable contacts between K49 and pS20 facilitated by the proline-induced
conformational changes. To test this, a K49A mutation was introduced into 14-3-3ζ and
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Figure 2.5 A comparison of the orientation of 14-3-3ζ's K49 side-chain in the 14-33ζ/Cby and 14-3-3ζ/Raf1 (PDB: 3CU8) complexes
Cby is represented by the green sticks and Raf1 by the light pink sticks. K49 in the 14-33ζ/Cby and 14-3-3ζ/Raf1 complexes is shown in yellow and dark pink, respectively.
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ITC titrations were performed with 18-mer WT and S22P Cby peptides. Interestingly,
the data show that the K49A mutation only had a minor effect (WT – 4.9 µM, K49A –
5.5 µM, ΔΔG ~ 0.1 kcal/mol) on the binding to the WT Cby peptide, however, the mutant
bound with lower affinity to the S22P Cby peptide compared to the WT 14-3-3ζ (WT –
0.38 µM, K49A – 1.8 µM, ΔΔG ~ 1.0 kcal/mol) (Table 2.1 and 2.2, Figure 2.6).
Therefore, K49 appears to at least partially responsible for the enhanced binding affinity
observed between WT 14-3-3ζ and the S22P Cby peptide.

Figure 2.6 14-3-3ζ K49A ITC thermograms
ITC thermograms for the A. WT Cby 18-mer and B. Cby S22P 18-mer titrated to 14-3-3ζ
K49A.

2.3.5

Probe for secondary interactions between 14-3-3ζ and Cby
using NMR spectroscopy

The crystal structure of 14-3-3ζ/Cby complex clearly reveals the molecular basis of
primary interactions between 14-3-3ζ and the non-canonical mode II binding motif within
Cby. However, like most of the 14-3-3/phosphopeptide structures available to date, the
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lack of electron density for residues outside the phosphorylated binding motif of Cby
hinders our understanding of the secondary interactions in complex formation. Notably,
our ITC results showed that the Cby 18-mer (12KTPPRKSA(pS)LSNLHSLDR29) used in
the crystallographic study has a significantly higher affinity compared to the 7-mer
(16RKSA(pS)LS22; the minimal 14-3-3 binding motif) for 14-3-3ζ. However, only
residues 23NLH25 outside the minimal binding motif were observable in the crystal
structure. Of the three, only the L24 side-chain is buried within the interface, projecting
toward a hydrophobic patch consisting of 14-3-3ζ residues L216 and I217. Intriguingly,
immunoprecipitation experiments performed by Li et al.[14] demonstrated that an alanine
substitution at L24 on Cby abolished binding to 14-3-3ζ. Our ITC titrations with the Cby
18-mer comprising the L24A mutation revealed that its interaction with 14-3-3ζ was
indeed impaired but not abolished, binding approximately 4-fold weaker than the wildtype peptide with a KD ~21 µM (Table 2.1 and 2.2, Figure 2.2). To gain a more thorough
understanding of the secondary interactions between 14-3-3ζ and Cby, we sought to
determine if there are additional regions in 14-3-3ζ that interact with the Cby 18-mer
compared to the 7-mer using NMR chemical shift mapping, a powerful technique for
identifying binding interfaces in solution.
Due to the relatively high molecular weight of the 14-3-3ζ dimer (~56 kDa),
deuterated protein samples were used in our NMR studies. An initial 1H-15N TROSYHSQC spectrum of 14-3-3ζ displayed many well-dispersed resonance signals along with
a small number of extremely intense peaks (Figure 2.7). These strong peaks do not
display any chemical shift changes upon titration of the unlabeled 18-mer Cby peptide,
indicating that their corresponding residues are not involved in the interaction (Figure
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2.7). However, their presence in the 1H-15N TROSY-HSQC spectrum unavoidably
complicates the spectral analysis by masking many underlying resonances. We
speculated that these high intensity resonances originate from 14-3-3ζ’s C-terminal tail,
which has been shown to be disordered [41]. With this in mind, we have generated the
14-3-3ζΔC12 construct, which is full-length 14-3-3ζ with the C-terminal 12 residues
being removed. The 1H-15N TROSY-HSQC of 14-3-3ζΔC12 overlays almost perfectly
with that of 14-3-3ζ, except that the highly intense peaks are no longer observable,
confirming that these resonances originate from the C-terminal tail. Importantly, ITC
experiments show that 14-3-3ζΔC12 binds to Cby peptides with almost the same affinity
as full-length 14-3-3ζ (Table 2.1 and 2.2, Figure 2.8).
Backbone resonance assignments for 1HN, 15N, 13Cα and 13Cβ were obtained for
14-3-3ζΔC12 (Figure 2.9 A). We were able to assign 82 % of the 1HN and 15N
resonances of non-proline residues, 81 % of all 13Cα and 81 % of all 13Cβ resonances.
The presence of weak peaks prevented a higher percentage of resonance assignments.
The residue-specific secondary structure propensity (SSP) scores using 13Cα/β chemical
shifts [42] indicate that the protein is, as expected, largely α-helical (Figure 2.9 B).
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Figure 2.7 1H-15N TROSY-HSQC of 2H/13C/15N 14-3-3ζ in the absence (blue) and
presence of a 1:1 molar ratio of the Cby 18-mer (red).
Circled resonances represent the intense signals arising from 14-3-3ζ’s disordered Cterminal tail. A zoomed-in view displays the intense signals derived from 14-3-3ζ’s
disordered C-terminal tail.
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Figure 2.8 ITC thermograms for 14-3-3ζΔC12
ITC thermograms for the A. Cby 13-mer and B. Cby 18-mer titrated to 14-3-3ζΔC12.
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Figure 2.9 Backbone resonance assignment of 14-3-3ζΔC12
A. 1H-15N TROSY-HSQC spectrum and backbone resonance assignment of 2H/13C/15N
labeled 14-3-3ζΔC12. B. Secondary structure propensity (SSP) scores for 14-3-3ζΔC12.
SSP scores were calculated based upon the 13Cα/β chemical shifts.

62

2.3.6

Mapping the Cby peptides binding regions on 14-3-3ζΔC12
The nearly complete backbone assignment of 14-3-3ζΔC12 affords an opportunity

to map the binding regions of different Cby peptides on 14-3-3ζ in a highly efficient
manner. The 7-mer and 18-mer Cby peptides were titrated to 14-3-3ζΔC12 in a series of
NMR experiments to a final molar ratio of 3:1 (peptide:protein) for chemical shift
mapping (Figure 2.10 A). When comparing the 1H-15N TROSY-HSQC spectra of 14-33ζΔC12 in the apo and the 7-mer/18-mer Cby bound forms, a large number of chemical
shift changes as well as peak broadenings are observed. The chemical shift perturbations
were calculated for both titration sets and were mapped onto the 14-3-3ζ/Cby structure
(Figure 2.11 B & C, Figure 2.12 A). From the generated maps, the residues exhibiting
the largest chemical shift changes for both peptides are found within helices αC, αE and
αI, matching well with the binding interface observed in the crystal structure (Figure 2.11
A). Additional peaks within the binding cleft were broadened out over the course of the
titrations. For the Cby 18-mer titration, these peaks include M121, D124, Y125 and
A130 within αE, L170, L172, V176 and Y178 within αG, and I217, L220 and R222
within αI. Broadened resonances within the binding cleft are similar for the Cby 7-mer
titration, including F117, M121, D124 and A130 within αE, L170, L172, V176, F177
and Y178 within αG, and Y211 within αI. Even though residues that bond with the
phosphate group of S20 on Cby, R56, R127 and Y128, could not be assigned, residues
surrounding this basic patch either broaden out (M121, D124, Y125, V176) or exhibit
large chemical shift changes (V52, G53) as expected. Large chemical shift perturbations
or broadened resonances were not observed along the 14-3-3ζ dimer interface for either
peptide.
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Notably, the Cby 18-mer binding interface appears to be larger than that of the
pCby 7-mer. Many 14-3-3ζ residues within the loop between αH and αI (204-208),
along with N-terminal residues of αI (209-215) exhibit larger chemical shift perturbations
when titrated with the Cby 18-mer compared to the Cby 7-mer (Figure 2.13). Based on
the orientation of the peptide, we speculate that this region of 14-3-3 interacts with the Cterminal (26SLDR29) residues on the Cby 18-mer peptide.
Additional NMR titration experiments were performed with the Cby S22P 18-mer
to compare its binding interface with the WT. The chemical shift analysis (Figure 2.10 B
and 2.12 B) and subsequent mapping onto the 14-3-3ζ/Cby structure (Figure 2.11 D)
revealed a similar interface to that observed for the Cby WT 18-mer. Interestingly, while
the resonance signals of some residues in the αH - αI loop and residues within the 209215 range in αI shift similarly when titrated with the WT or S22P peptides, the T205,
L206, E209 and S210 peaks have much smaller shifts when titrated with the Cby S22P
18-mer. Having a proline at the +2 position may affect how the downstream C-terminal
residues interact with this loop region.
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Figure 2.10 NMR titration experiments of 14-3-3ζΔC12 with Cby peptides
A. 1H-15N TROSY-HSQC spectra of 14-3-3ζΔC12 alone (black) and with 3 molar
equivalents of the Cby 7-mer (red) and Cby 18-mer (blue). B. 1H-15N TROSY-HSQC
spectra of 14-3-3ζΔC12 alone (black) and with 3 molar equivalents of the WT Cby 18mer (blue) and Cby S22P 18-mer (blue).
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Figure 2.11 The mapping of chemical shifts on the crystal structure of the 14-33ζ/Cby complex
Due to the crowding of some peaks, the chemical shifts of some residues could not be
confidently traced and were excluded from the analysis. A. (Above) A monomer of the
14-3-3ζ/Cby crystal structure interface based on Cby residues (18SApSLSNLH25).
Residues R56, R127 and Y128 which contact the Cby phosphate group are coloured red,
residues interfacing the peptide are coloured cyan, and 14-3-3ζ residues coloured
magenta are found along the 14-3-3 dimer interface. (Below) The 14-3-3ζ dimer bound
to Cby. B. (Cby 7-mer), C. (Cby 18-mer) and D. (Cby S22P 18-mer). Residues with
traceable assigned resonances are coloured on a blue – white –yellow gradient (0 ppm to
0.1 ppm) based on their combined chemical shift [Δω = ((Δδ1H)2 +(0.2*Δδ15N)2)1/2] at a
3:1 peptide:protein ratio. Residues coloured in orange represent peaks that broadened out
to disappearance upon addition of peptide. Residues R56, R127 and Y128 are coloured
pink.
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Figure 2.12 Composite 1HN and 15N chemical shift perturbation analysis
Composite 1HN and 15N chemical shift perturbation [Δω = ((Δδ1H)2 +(0.2*Δδ15N)2)1/2]
analysis of 14-3-3ζΔC12 in the presence of three molar equivalents of the A. Cby 7-mer,
A. + B. Cby 18-mer and B. Cby S22P 18-mer. Due to the crowding of some peaks, the
chemical shifts of some residues could not be confidently traced and were excluded from
the analysis.
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Figure 2.13 Observed chemical shifts for 14-3-3ζΔC12 residues 204-215
Resonances shown for each residue include the apo state (black), Cby 18-mer bound-state
(blue) and the pCby 7-mer bound-state (red), at a 3:1 (pCby: 14-3-3ζΔC12) ratio.
*Residue Y211 is displayed at a 1.25:1 (Cby: 14-3-3ζΔC12) ratio as it broadens out to
disappearance at a 3:1 ratio with the Cby 7-mer. The Cby-18-mer bound-state is shown
in cyan with the 7-mer bound-state in magenta.
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2.3.7

Cby binds to all human 14-3-3 isoforms
From pull-down and coimmunoprecipitation experiments, Li et al. [13] found that

in addition to the 14-3-3ζ isoform, Cby interacts with the ε and η isoforms. ITC
experiments were designed to test whether Cby can bind to all human 14-3-3 isoforms
and to determine whether there are any large differences in affinity across the isoforms.
The ITC profiles for the Cby 18-mer/14-3-3 isoforms are shown in Figure 2.14 and the
fitted data are tabulated in Table 2.4 and 2.5. The Cby 18-mer peptide bound to all seven
isoforms with a spectrum of high nanomolar to low micromolar affinity, ranging from ~
500 nM for the η isoform to ~ 11 µM for the ε isoform.

2.3.8

14-3-3 phosphomimetic mutations fail to abrogate the 14-33/Cby 18-mer interaction
Further to the importance of 14-3-3 linker regions in target recognition, Mancini

et al. [49] suggested that phosphorylation at serine 186 on 14-3-3σ by the c-Jun Nterminal kinase (JNK) promotes the dissociation of Cby. Serine 186, located in the αGαH linker on 14-3-3σ, along with the corresponding residue on the ζ isoform, S184, were
each mutated to glutamate as a phospho-mimetic. Their binding to the Cby 18-mer was
measured by ITC (Figure 2.15, Table 2.4 and 2.5) and no significant difference in binding
affinity was observed for either mutant. Phosphomimicry may not be enough to promote
dissociation of the complex.
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Table 2.4 Thermodynamic parameters of Cby 18-mer binding to all 14-3-3 isoforms
Thermodynamic parameters for the binding of 12KTPPRKSA(pS)LSNLHSLDR29 Cby 18-mer
peptide to human 14-3-3 isoforms and mutants at 25°C.
Isoform

na

Kdb (10-6 M)

∆Hb (kcal/mol)

T∆Sb (kcal/mol)

∆Gb (kcal/mol)

14-3-3η

0.97 ± 0.00(2)

0.57 ± 0.02

-10.31 ± 0.05

-1.79

-8.53 ± 0.02

14-3-3γ

0.98 ± 0.00(4)

0.88 ± 0.04

-9.43 ± 0.06

-1.17

-8.27 ± 0.03

14-3-3β

0.95 ± 0.00(4)

1.45 ± 0.06

-11.56 ± 0.07

-3.61

-7.97 ± 0.02

14-3-3ζ

0.88 ± 0.00(4)

2.50 ± 0.10

-9.70 ± 0.07

-2.05

-7.65 ± 0.02

14-3-3ζ S184E

0.98 ± 0.00(4)

1.21 ± 0.05

-7.47 ± 0.04

0.61

-8.08 ± 0.04

14-3-3θ

0.93 ± 0.01

4.35 ± 0.14

-7.73 ± 0.06

-0.41

-7.32 ± 0.02

14-3-3σ

0.93 ± 0.01

5.02 ± 0.18

-7.88 ± 0.09

-0.65

-7.23 ± 0.02

14-3-3σ S186E

0.94 ± 0.00(5)

3.80 ± 0.04

-6.70 ± 0.05

0.69

-7.39 ± 0.06

14-3-3ε

0.85 ± 0.04

12.92 ± 0.81

-9.14 ± 0.50

-2.47

-6.67 ± 0.04

a

Binding stoichiometry of monomeric 14-3-3 and Cby peptide.
Kd is the dissociation constant. ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs
free energy upon binding at T=298.15 K, respectively.
b

Table 2.5 Duplicate thermodynamic parameters for the binding of Cby 18-mer to
14-3-3 isoforms
Thermodynamic parameters for the binding of 12KTPPRKSA(pS)LSNLHSLDR29 Cby peptide to
human 14-3-3 isoforms and mutants at 25°C obtained using ITC.
Isoform

na

Kdb (10-6 M)

∆Hb (kcal/mol)

T∆Sb (kcal/mol)

∆Gb (kcal/mol)

14-3-3η

0.88 ± 0.00(2)

0.46 ± 0.03

-10.73 ± 0.04

-2.08

-8.65 ± 0.03

14-3-3γ

1.02 ± 0.03

0.63 ± 0.03

-9.67 ± 0.06

-1.21

-8.47 ± 0.03

14-3-3β

0.90 ± 0.01

2.08 ± 0.11

-11.57 ± 0.11

-3.81

-7.76 ± 0.03

14-3-3ζ

0.87 ± 0.01

2.85 ± 0.14

-10.06 ± 0.09

-2.49

-7.57 ± 0.03

14-3-3ζ S184E

1.02 ± 0.00(3)

1.29 ± 0.04

-7.23 ± 0.03

0.80

-8.03 ± 0.03

14-3-3θ

0.94 ± 0.00(5)

4.44 ± 0.17

-7.64 ± 0.06

-0.34

-7.31 ± 0.02

14-3-3σ

0.88 ± 0.01

4.29 ± 0.21

-8.34 ± 0.11

-1.02

-7.33 ± 0.03

14-3-3σ S186E

0.92 ± 0.00(5)

3.63 ± 0.04

-6.67 ± 0.05

0.75

-7.42 ± 0.06

14-3-3ε

0.80 ± 0.03

10.59 ± 1.05

-9.87 ± 0.54

-3.07

-6.79 ± 0.06

a

Binding stoichiometry of monomeric 14-3-3 and Cby peptide.
b
Kd is the dissociation constant. ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs
free energy upon binding at T=298.15 K, respectively.
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Figure 2.14 ITC thermograms for Cby 18-mer binding to all 14-3-3 isoforms
ITC thermograms for phosphorylated Cby 18-mer titrated into the seven human isoforms
of 14-3-3. A. 14-3-3β B. 14-3-3γ C. 14-3-3ε D. 14-3-3ζ E. 14-3-3η F. 14-3-3θ G. 14-33σ

71

Figure 2.15 ITC thermograms for Cby 18-mer binding to 14-3-3 phosphomimetics
ITC thermograms for phosphorylated Cby 18-mer titrated into A. 14-3-3ζ S184E and B.
14-3-3σ S186E.
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2.4

Discussion

The molecular basis of the interaction between 14-3-3ζ and Cby was extensively
investigated by using a combination of X-ray crystallography, NMR spectroscopy, and
ITC. Our ITC results show that even though phosphorylation of Cby-S20 is critical for
the complex formation (as Cby peptides comprising S20D and S20E phospho-mimetics
failed to bind to 14-3-3ζ), residues outside the 14-3-3 binding-motif also play an
important role in the interaction. This is supported by the finding that a short, 7-residue
phosphopeptide of Cby comprising the minimal 14-3-3 binding-motif bound 10-fold
weaker compared to a longer, 18-residue phosphopeptide. A similar observation was
made in a recent study of 14-3-3/α-integrin tail complexes, demonstrating that a 30residue α4-integrin peptide comprising its 14-3-3-binding motif bound up to 15 times
tighter to 14-3-3ζ than an 11-residue peptide [40]. Interestingly, in the same study, short
and long phosphopeptides comprising the 14-3-3 binding motif for the β2-integrin bound
with nearly the same high affinity, suggesting that secondary interactions from flanking
residues are likely sequence specific.
Another interesting finding from our ITC experiments is that the phosphorylated
Cby peptides comprising a mutation at the pS + 2 position to the canonical proline (S22P)
bind ~15 fold tighter than the WT peptides. Our crystal structure provides molecular
insight into the target binding specificity of 14-3-3. Based on available crystal structures
of various 14-3-3 isoforms in complex with phosphorylated peptides comprising type I or
type II binding motifs (for example, PDB: 1QJA [31], 1QJB [31], 3MHR [43]), the K49
(ζ sequence) side chain commonly forms a hydrogen bond with the phosphate group on
pSer. However, in the 14-3-3ζ/Cby crystal structure, the side chain of S22 positions
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between K49 and R56 of 14-3-3ζ and sterically hinders the interaction between K49 and
pS20. Interestingly, introducing K49A mutation to 14-3-3ζ does not affect its affinity for
the WT Cby peptide, but the binding affinity to the S22P peptide was reduced by ~5 fold.
From these results, we speculate the S22P mutation of Cby promotes a conformational
change in the bound state, allowing K49 on 14-3-3ζ to form hydrogen bond with the
phosphate group on S20. However, it should be noted that there are examples of peptides
containing a +2 proline co-crystallized with 14-3-3 proteins where K49 is either not
making any direct contacts with the ligand (PDB: 4FL5) or it interacts with other residues
within the phosphopeptides (PDB: 3UAL [44], 4IEA [45]) instead of the phosphorylation
site. Additionally, a proline at the +2 position is not absolutely essential for a K49 –
phosphate group interaction. This contact is observed in the 14-3-3γ/tyrosine
hydroxylase structure (PDB: 4J6S [46]) and in the 14-3-3ζ/alpha-4 integrin, which both
have a leucine at the +2 position.
With only 8 of the 18 residues in the Cby 18-mer peptide resolved in the crystal
structure, it is likely that any secondary contacts made by flanking residues are very
dynamic. This is a common issue in the co-crystallization of 14-3-3 proteins and
peptides. Typically, only short regions (4-10 residues comprising residues nearby the
pS/pT) within longer phosphopeptides are resolved. Because significant secondary
interactions may be critical to 14-3-3ζ’s interaction with Cby, we elected to pursue NMR
spectroscopy as a means of further characterizing the complex.
Chemical shift analysis of 1H-15N TROSY-HSQC titration experiments, performed
by titrating the 7-mer and 18-mer Cby peptides into isotopically labeled 14-3-3ζΔC12,
allowed for chemical shift mapping to reveal any differences in the binding interface
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between both peptides. We found that 14-3-3ζ residues 204-215 are involved in the
interaction with the Cby 18-mer but not the 7-mer. Based on the orientation of the
peptide in the crystal structure, this would correspond to the residues C-terminal to the
pS20, 23NLHSLDR29, making transient contacts with this region of 14-3-3ζ. Chemical
shift analysis of the Cby S22P 18-mer bound to 14-3-3ζΔC12 revealed a similar binding
site to that of the WT 18-mer, however some variability in shifts for residues within the
204-215 range were observed. This suggests that the +2 residue can affect how
downstream C-terminal residues interact with 14-3-3ζ. A +2 proline is of particular
interest because while it is most commonly observed bound in a trans conformation (e.g.
1QJA [31]) it has been observed bound in the cis conformation (e.g. 1QJB [31]).
Residues 203-210, corresponding to 14-3-3ζ’s αH-αI linker, have been shown to be
part of a secondary binding site with another 14-3-3 target [30]. The crystal structure of
the 14-3-3ζ/phosphorylated-AANAT complex, the only full-length protein to be solved in
complex with 14-3-3, demonstrates that this linker is used by 14-3-3ζ to bind AANAT,
highlighted by the 14-3-3ζ residue E208 making a salt bridge with R53 of phosphorylated
AANAT, located in the globular region of the protein. Additionally, this linker region
has been implicated in ligand discrimination between 14-3-3 isoforms [47,48]. For
instance, the phosphatase Cdc25C can bind to all 14-3-3 isoforms except for σ; however,
the mutation of divergent residues within 14-3-3σ’s αH-αI linker to those conserved
across all other isoforms enables the engineered σ to bind Cdc25C [48]. When we tested
the binding of the Cby 18-mer to all 14-3-3 isoforms, a high nanonmolar to low
micromolar spectrum of affinities was observed. The differences in affinity among the
14-3-3s may be attributed to sequence variations along the αH-αI or αG-αH linkers of
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the isoforms. There are potentially greater differences in affinity across isoforms in the
context of full-length Cby.
Building on this work, future studies may elucidate how the complex forms in the
context of full-length Cby. It is conceivable that two Cby molecules could retain a
coiled-coil structure while each is bound to 14-3-3ζ (Figure 2.16). Because of the
orientation each 14-3-3ζ monomer adopts upon dimerization, the Cby residues lying on
the C-terminal end of serine 20 will exit the binding interface at opposing ends of the 143-3ζ dimer. Since the N-terminal residues (1-64) of full-length Cby are disordered [19] it
is feasible that each bound Cby molecule retains the flexibility necessary to orient itself
to form a coiled-coil from residues 73-100, as well as to bind to the 88-kDa β-catenin.
The model (Figure 2.16) is consistent with the results of Li et al.[13], which
demonstrated that binding of Cby to β-catenin is not interfered by the increased level of
14-3-3. We are aware that a Cby dimer binding to the 14-3-3 dimer could presumably
lead to a stronger interaction between the two molecules than what was reported in this
study due to avidity. How the complex ultimately forms, i.e. its stoichiometry and
conformation, will aid in providing the mechanistic basis by which the two proteins
recruit β-catenin to form a trimolecular complex and promote β-catenin’s nuclear
exclusion.
Also of interest is the interplay of Cby’s interactions with 14-3-3 and CRM1.
Cby’s 14-3-3 binding motif is juxtaposed with its nuclear export signal (NES)
(21LSNLHSLDR29). Immunoprecipitation experiments by Li et al. [14] revealed that 143-3 enhanced the Cby-CRM1 interaction in a dose-dependent manner. It was postulated
that 14-3-3 might induce a conformational change in Cby to expose its NES for CRM1
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Figure 2.16 The 14-3-3ζ, Cby, β-catenin tripartite complex.
Model of dimeric 14-3-3ζ bound to two molecules of full-length Cby. The models of two
full-length Cby proteins have disordered residues 30–73 of the N-terminus and 100–126
of the C-terminus presented in a highly extended fashion, and are shown forming a
coiled-coil from residues 73–100. β-catenin (PDB: 2Z6H) is shown with its Cby bindingsite (helix C) in red which then binds along the C-terminus (64–126) of Cby.

77

recruitment. In doing so, CRM1 could then mediate the nuclear exclusion of Cby. Our
crystal structure demonstrates that this mechanism may not be the case. The consensus
NES sequence is Φ1(X2–3)Φ2(X2–3)Φ3XΦ4, where Φ represents critical hydrophobic
residues L, I, V, F or M and X is any amino acid [50,51]. In determined crystal structures
of CRM1/target complexes, the critical hydrophobic residues are buried in a hydrophobic
cleft formed by HEAT repeats 11 and 12 of CRM1 [52,53]. The hydrophobic residues on
Cby’s NES correspond to L21, L24 and L27. From our 14-3-3/Cby crystal structure, the
L21 and L24 sidechains are projected toward 14-3-3’s binding cleft, making them
inaccessible for CRM1. Residues (26SLDR29) are unobservable in our structure and thus
their accessibility remains unknown. However, Li et al. [14] demonstrated that a L27A
mutation to Cby did not affect the Cby/CRM1 interaction, and showed normal, WT
subcellular distribution. Meanwhile, L21A and L24A mutations abolished the interaction
with CRM1 and led to the nuclear sequestration of Cby. As such, 14-3-3 may need to be
dissociated from Cby to allow for the CRM1 interaction. Further cell experiments and
structural studies of the Cby/CRM1 complex are needed to comprehend how 14-3-3 and
CRM1 work in concert to promote the cytoplasmic sequestration of Cby.
Finally, NMR studies are critical to the characterization of 14-3-3 interactions as
their interactome is predicted to predominantly consist of disordered targets [27]. The
backbone resonance assignment of 14-3-3ζ completed in this work therefore will not just
facilitate the studies of 14-3-3ζ with Cby, it will be invaluable for probing interactions
between 14-3-3ζ and a continually growing list of protein targets by NMR. Such studies
may allow the identification of ligand-binding interfaces on 14-3-3 in an efficient manner
as illustrated in this work. Moreover, with 14-3-3ζ over-expression associated with
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tumour progression and chemoresistance (reviewed in Matta et al. [54]), the protein is an
attractive therapeutic target in cancer. With the availability of the backbone resonance
assignment of 14-3-3ζ, NMR titration can be a quick way to test the binding/determine
the binding site of small molecule or peptide 14-3-3 inhibitors [55,56]. Similarly, this
may also be done for a number of recently discovered 14-3-3 protein-protein smallmolecule stabilizers [55,56], which offer an alternative approach to modulating 14-3-3
activity.
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Chapter 3

3

Conformational characterization of the intrinsically
disordered protein Chibby: Interplay between structural
elements in target recognition

3.1 Introduction
The Wnt/β-catenin pathway, a signaling cascade whose roles include embryonic
development and stem-cell self-renewal, has been linked to a number of human diseases
upon its dysregulation, including cancer [1,2,3]. Human Chibby (Cby), an evolutionarily
conserved protein, plays a critical role in this pathway by functioning as an antagonist of
the transcriptional co-activator β-catenin, the key mediator of Wnt signaling [4]. Cby
achieves its antagonistic activity via two mechanisms. First, Cby interacts with β-catenin,
forming a complex that prevents β-catenin from binding to and activating Tcf/Lef
transcription factors [4]. Secondly, Cby/β-catenin forms a tripartite complex with 14-3-3
proteins to promote β-catenin’s export from the nucleus, further suppressing Wnt
signaling [5,6].
Besides binding to β-catenin and 14-3-3, Cby participates in the Wnt signaling
pathway by interacting with several other partners including nuclear export receptor
CRM1 [5], importin-α [5,7], and Thyroid Cancer 1 (TC-1, also known as C8orf4) [8,9].
In particular, TC-1, which was originally identified as a gene highly expressed in thyroid
cancer, positively regulates Wnt signaling through its interaction with Cby [10]. By
competing with β-catenin for binding to Cby, TC-1 enables free β-catenin to up-regulate
Wnt target genes [9]. Recent studies show that TC-1 is also associated with ovarian
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carcinoma [11], tongue squamous cell carcinomas [12], and lung cancer [13], all likely
through the Wnt/β-catenin pathway.
In addition to these binding partners, Cby interacts with several proteins outside
of Wnt signaling such as CEP164 [14], NBPF1, clusterin [15], polycystin-2 and GM130
[16]. Even though numerous Cby interactors have been identified, the molecular details
of most of these interactions remain largely unknown. It has been suggested that the
ability of Cby to bind multiple targets is facilitated by its partially disordered nature [17].
In our previous work and that of others [7,17], biophysical and biochemical techniques,
which include circular dichroism (CD) spectropolarimetry, nuclear magnetic resonance
(NMR) spectroscopy, cross-linking and gel filtration experiments, were used to
characterize the structure of Cby. The results demonstrated that the N-terminal half of
Cby is largely unstructured, whereas its C-terminal half is α-helical and harbors a
predicted coiled-coil domain [7,17]. The coiled-coil domain allows for the selfassociation of Cby in solution, where it exists predominantly as a homodimer [7]. These
distinct structural elements of Cby are important for mediating its interactions with
various targets. For example, in Wnt/β-catenin signaling, the disordered N-terminus of
Cby binds to the 14-3-3 proteins (upon phosphorylation at residue 20 by the kinase Akt)
[5,18] and the nuclear export receptor CRM1 [5], whereas its C-terminal half is
responsible for binding to β-catenin [4], TC-1 [9], and importin-α [5,7].
Proteins containing both unstructured regions and coiled-coil motifs are
widespread. As in the case of Cby, utilization of both types of structural elements may be
critical to their biological function [19,20,21,22]. For instance, disordered regions can
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tune the affinity for protein interaction partners [23]. Increasing or decreasing these
affinities may be accomplished by different mechanisms [23,24]. Examples include
providing enhanced stability to the protein or its complex [25], as well as disorder-toorder transitions upon interaction [26] or autoinhibition [27]. In this work, we sought to
determine how the disordered regions of Cby affect the stability and target recognition of
its coiled-coil domain.
NMR spectroscopy is a valuable tool to dissect the structural details and dynamics
of partially disordered proteins [28,29,30]. However, in the case of Cby, its
characterization by NMR spectroscopy has proven to be a challenge. Previous work in
our lab showed that most of the NMR resonances for Cby’s C-terminal half are too broad
to be observed under non-denaturing conditions, likely due to the monomer/dimer
conformational exchange or formation of higher oligomeric forms [17]. This behavior is
not unique to Cby, as severe NMR broadening has been seen in other proteins that are
comprised of long disordered regions and coiled-coil motifs [31,32,33].
Hydrogen/deuterium exchange-mass spectrometry (HDX-MS) is another widely
used technique to analyze protein folding, structure, dynamics, and interactions
[34,35,36,37,38]. Backbone amide hydrogens within disordered regions will exchange
rapidly upon D2O exposure, in comparison to residues in well-folded, rigid regions,
where slow D2O uptake is mediated by conformational fluctuations that lead to transient
opening of hydrogen bonds. In this work, we combined HDX-MS, NMR spectroscopy,
CD, and isothermal titration calorimetry (ITC) to investigate the interplay of different
Cby structural elements during target (TC-1) recognition.
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3.2
3.2.1

Materials and Methods
Protein Expression and Purification

The expression and purification protocols for full-length Cby, CbyΔC20 (deletion
of the last 20 residues of Cby), N-Cby (residues 1-63) and TC-1 were carried out as
described previously [8,10,17]. The pET-15b plasmid containing human TC-1 with an Nterminal His6-tag was a gift from Dr. E. Chua (University of Sydney, Australia) [10]. The
His-tags remained uncleaved from the recombinant Cby constructs to increase their
solubility.
C-Cby (residues 67-126) and Coil-Cby (residues 67-104) were cloned into the
Gateway destination vector pDEST-HisMBP. The His-MBP fusion constructs were
expressed in Esherichia Coli (E. coli) BL21(DE3) pLysS in M9 minimal media and
induced with 0.75 mM isopropyl-β-D-thiogalactopyranoside (IPTG; Bioshop). For pulldown assays the His-tagged proteins were purified from crude lysate by affinity
chromatography using Ni-Sepharose 6 Fast Flow beads (Amersham Biosciences). To
purify C-Cby and Coil-Cby, the His-MBP tag were cleaved by overnight incubation with
tobacco etch virus (TEV) protease at room temperature in 20 mM Tris-HCl, 50 mM
NaCl, pH 7.5. The tag-less Cby constructs precipitated out of solution during the
cleavage and were subsequently re-solubilized in 20 mM Tris-HCl, 100 mM NaCl, 6 M
Guanidine, pH 7.5. The protein was passed through a Superdex 200 column (GE
Healthcare) in the same guanidine-containing buffer. For refolding, C-Cby was dialyzed
immediately into 10 mM ammonium acetate, pH 5.0 while Coil-Cby was first dialyzed
into 10 mM sodium acetate, 8 M urea, pH 5.0 and later into 10 mM ammonium acetate,
pH 5.0. All experiments of this work were performed at pH 5.0 as both Cby and TC-1 are
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soluble at low pH. All DNA constructs used in this work were sequenced. Purified
proteins were analyzed on SDS-PAGE for purity and mass spectrometry analysis ensured
they were the correct mass.

3.2.2

Peptide Synthesis
The Cby peptide comprising its C-terminal 25 residues (CbyC25) was purchased

from the Tufts University Core facility. The peptide was dissolved and dialyzed in 10
mM ammonium acetate, pH 5.0 for NMR experiments.

3.2.3

Hydrogen/Deuterium Exchange – Mass Spectrometry
HDX-MS of Cby was performed by mixing protein stock solution in a 1:9 ratio

with D2O-based labelling buffer at pH-meter reading of 5.0. The final protein
concentration was 2 µM. Aliquots were removed at selected time points ranging between
1 min and 2 h. These aliquots were quenched at pH 2.4 by addition of HCl on ice,
followed by flash freezing in liquid nitrogen. Prior to analysis the aliquots were rapidly
thawed to ~0 °C and injected into a nanoACQUITY HDX/UPLC (Waters, Milford,
MA)[39] for peptic digestion, trapping, and peptide separation. A peptic cleavage map of
Cby is provided in Figure 3.1. Deuteration percentages were calculated as 100% × (m –
m0)/ (m100 – m0) where m is the centroid m/z for the partially deuterated peptide of
interest, and where m0 and m100 correspond to minimally and fully deuterated controls,
respectively [39].

3.2.4

Circular Dichroism Spectropolarimetry
CD spectra and thermal melting curves were collected on a Jasco J-810

spectropolarimeter (Easton, MD). Spectra of the various Cby constructs (0.15 mg/mL to
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0.30 mg/mL) were collected at 25 °C in 10 mM ammonium acetate, pH 5.0, with 5
accumulated scans for each construct. For the melting curves, the temperature was
scanned from 15 °C to 95 °C, with the ellipticity monitored at 222 nm. The analysis
program CDSSTR included in the DichroWeb online analysis software was used to
deconvolute the CD spectra [40]. Deconvolution was performed using the SMP180
(optimized for 190-240 nm) reference set [41].

3.2.5

NMR Spectroscopy
NMR experiments were carried out on a Varian Inova 600-MHz spectrometer

equipped with xyz-gradient triple resonance probe at 25 °C in 10 mM ammonium acetate
buffer, pH 5.0. Samples contained 10% D2O and 1 mM 2,2-dimethyl-2-sila-pentane-5sulfonic acid (DSS) as an internal standard for chemical shift referencing. Data were
processed using NMRPipe [42] and analyzed using NMRView [43]. The backbone
assignment of TC-1 was previously completed by our lab (BMRB accession code: 15141)
[8].

3.2.6

Isothermal Titration Calorimetry (ITC)
ITC experiments were performed on a VP-ITC instrument (MicroCal) at 25 °C in

10 mM ammonium acetate, pH 5.0. 8 µL aliquots of 230 µM TC-1 were titrated stepwise
into the 1.4 mL sample cell containing 20 µM C-Cby. Titrations of TC-1 to buffer and
buffer to C-Cby revealed negligible heat changes. The dissociation constant (Kd), molar
binding stoichiometry (n) and the binding enthalpy (∆H), entropy (∆S) and Gibbs free
energy (∆G) were determined by fitting the binding isotherm to a one-site model with
MicroCal Origin7 software. Protein concentrations were determined from amino acid
analysis (Amino Acid Analysis Facility, SickKids, Toronto, ON).
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3.3
3.3.1

Results
Identifying the coiled-coil region of Cby using HDX-MS

Owing to previous difficulties encountered during NMR-based characterization
attempts of full-length Cby [17], we resorted to HDX-MS. The primary goal of these
measurements was to delineate the coiled-coil dimerization domain of Cby. Figure 3.1
displays the Cby peptic peptides used in the HDX-data analysis while Figure 3.2 shows
the deuterium uptake curves for these peptides. Deuteration was quasi-instantaneous for
the N-terminal half of Cby, i.e., deuterium levels of > 90% were observed already for the
first experimental time point of 1 min. Similarly, residues 102-126, which make up the
very C-terminal end of Cby, exhibited extremely rapid deuterium uptake. Strong HDX
protection is observed in peptides that are near (residues 53-59) and within (residues 6090) the predicted boundaries of Cby’s coiled-coil domain (residues 68-102) [7,44], with
nearly no exchange in the range of residues 91-98.
For visualization of these data, the deuteration percentages were mapped onto a
structural model of dimeric Cby for t = 60 min (Figure 3.3). In this model, the coiled-coil
is presented as residues 73-100, corresponding to four turns of heptad repeats. However,
we should point out that the N-terminal boundary of the coiled-coil domain is not clearly
defined in our HDX data since only relatively large peptic fragments (60-84 and 60-90)
were obtained for this region. In contrast, it is clear that the coiled-coil ends around
residues 98, as the significant protection observed is immediately succeeded by rapid
deuterium uptake in the 102-111 peptic fragment. For the rest of the model, Cby’s Ntermini and very C-termini (which will be denoted as its C-terminal extension from now
on) are displayed in a largely extended state.
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Figure 3.1 Sequence of human Cby and peptides used in HDX-MS data analysis
Sequence of human Cby and its His tag (lower case, grey colour). Black lines below the
sequence are the peptic peptides used in the HDX-MS data analysis, and the broken lines
are peptides originating from solely the His-tag. Colour scheme: negatively charged
residues in red, positively charged residues in blue, polar residues in green and non-polar
residues in black.
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Figure 3.2 HDX kinetics of peptides in Cby
The 28-residue His-tag and Cby residue numbers are indicated in each panel. Lines are
bi-exponential fits. Standard deviations of triplicate measurements are shown as error
bars.
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Figure 3.3 HDX-MS data of Figure 3.2 mapped onto a structural model of Cby for
t=60 min
The 126-residue Cby is shown as a dimer. Residues 1-72 are shown in a highly extended
state, the coiled-coil is comprised of residues 73-100 and residues 101-126 are displayed
in a disordered form. The colouring represents a range of deuteration percentages.
Peptide mapping did not cover the grey regions.
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3.3.2

The disordered N-terminal half and C-terminal extension of
Cby
As identified by HDX-MS, Cby contains two disordered regions of different

length flanking the coiled-coil motif. We sought to determine whether these two
unstructured segments have differing effects on the stability of the coiled-coil structure.
A number of truncated Cby constructs were generated for this purpose (Figure 3.4). First,
we tested if Cby’s C-terminal extension plays a role in the formation of the coiled-coil by
truncating the last 20 residues of Cby (CbyΔC20). A CD spectrum of CbyΔC20 in 10
mM ammonium acetate, pH 5.0 is highly similar to that of full-length Cby (Figure 3.5 A).
Deconvolution of the spectra using the DichroWeb software [40] gives 30% helical, 21%
strand and 49% disordered/turn structure for the full-length Cby and 41% helical, 17%
strand and 42% disordered/turn for CbyΔC20. The data indicate that the C-terminal 20
residues are not structured and that the helical content of Cby is maintained upon deletion
of this disordered extension. Notably, the CD spectrum of a synthetic construct
comprising the C-terminal 25 residues of Cby (CbyC25), shows that the C-terminal
extension is largely disordered but does have α-helical propensity (deconvolution: 42%
helical, 12% strand and 46% turns/disordered) (Figure 3.5 C).
Next, we investigated the effect of C-terminal truncation on the thermal stability
of the coiled-coil motif. Figure 3.5 B shows the CD thermal denaturation profiles of wildtype Cby and CbyΔC20. For the full-length Cby, the ellipiticity at 222 nm gradually
becomes less negative as the temperature increases from 20 to 50 oC, while the signal
remains steady for the truncated CbyΔC20 over this temperature range. Once the
temperature reaches ~60 oC, both constructs display a significant increase (becoming less
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negative) in ellipiticity, signifying the melting of the coiled-coil. A thermal melt of the
CbyC25 peptide shows a gradual loss of signal at 222 nm in the 20-50 oC range, which
likely explains the differences between the thermal denaturation profiles of wild-type
Cby and CbyΔC20 in that temperature range (Figure 3.5 B).
While the thermal denaturation of the full-length Cby is reversible, as the CD
spectrum of the protein at 25 oC is identical before and after the melt, CbyΔC20
precipitates upon denaturation. Also, during optimization of the CbyΔC20 purification
strategy, we observed that the truncated version tends to aggregate in the presence of
NaCl at low concentrations (50 mM) while full-length Cby remains soluble in 100 mM
NaCl up to a protein concentration of 200 µM. Taken together, these observations
suggest that the C-terminal extension is important for Cby’s solubility, consistent with
the prevalence of charged side chains in this region (Figure 3.1).
An overlay of the 1H-15N HSQC NMR spectra of full-length Cby and
CbyΔC20 is shown in Figure 3.6. Similar to the full-length protein, only peaks from the
N-terminal half of CbyΔC20 can be observed in the HSQC spectrum. Consistent with the
CD data, the NMR spectrum suggests that Cby’s coiled-coil structure remains intact upon
deletion of the C-terminal extension, rendering the peaks from this region unobservable
by NMR. Notably, truncation of the C-terminal extension of Cby does not induce
significant chemical shift changes or intensity attenuation to the signals originating from
the N-terminal half, indicating that there are no long-range interactions between the Nand C-terminal disordered regions of Cby.
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Figure 3.4 Cby constructs used in this study
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Figure 3.5 CD spectra and thermal melts of Cby constructs
A. CD spectra of full-length Cby and Cby∆C20. Displayed spectra are the average of 5
scans. B. Thermal melts of full-length Cby and Cby∆C20 monitored using CD at 222
nm. C. CD spectra of C-Cby, Coil-Cby and CbyC25. Displayed spectra are the average
of 5 scans. D. Thermal melts of C-Cby, Coil-Cby and CbyC25 monitored using CD at
222 nm.
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Figure 3.6 NMR spectra of full-length Cby and CbyΔC20
1
H-15N HSQC NMR spectrum of full-length Cby (black) overlayed with a 1H-15N HSQC
of Cby∆C20 (red) (spectra collected at 100 µM).
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Next, we sought to characterize isolated C-terminal half of Cby in the absence of
the disordered N-terminus. A CD spectrum reveals that C-Cby (residues 67-126) is
largely helical (Figure 3.5 C). The deconvoluted procedure reports 64% helical, 3%
strand and 33% disordered/turn. The [θ]222/[θ]208 ratio is ≈ 1, which is indicative of
coiled-coil structure [45]. A thermal melt of C-Cby, using CD monitored at 222 nm,
displays a profile similar to that of full-length Cby, where a broad transition is observed
between 20 and 70 oC (Figure 3.5 D). Like full-length Cby, C-Cby could completely
refold after thermal denaturation. A HSQC spectrum collected for isolated C-Cby only
contains a few broad peaks, indicating that most of the NMR signals from the coiled-coil
motif and C-terminal extension in this construct remain largely unobservable (Figure
3.7).
After extensive efforts, we managed to purify the coiled-coil domain of Cby
(Coil-Cby, residues 67-104), despite its significantly lower solubility relative to the other
constructs. A HSQC spectrum of Coil-Cby has no detectable peaks, while the
deconvoluted CD spectrum returns 80% helical and 20% disordered/turn and the
[θ]222/[θ]208 ratio ≈ 1 (Figure 3.5 C). Its thermal denaturation profile, like all Cby
constructs comprising the coiled-coil domain, displays a sharp reduction in signal
between 60-70 oC (Figure 3.5 D). Similar to CbyΔC20, Coil-Cby aggregated upon
thermal denaturation.
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Figure 3.7 NMR Spectra of C-Cby
Overlay of 1H-15N HSQC spectra of C-Cby in the absence (black) and presence (red) of
TC-1 at a 1:1.5 ratio (C-Cby 100 µM:TC-1 150 µM).
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3.3.3

Disordered regions of Cby tune its binding affinity to TC-1
Focusing on the Cby/TC-1 interaction, we next investigated to what extent target

recognition of Cby is modulated by specific structural elements, i.e., the coiled-coil
domain, or the N- and C-terminal disordered regions. TC-1 functions as a positive
regulator of Wnt signaling by competing with β-catenin in binding the C-terminal half of
Cby [9]. Previous structural characterization of TC-1 by our lab established that the
predominantly disordered TC-1 contains three regions with α-helical propensity in its Cterminal half and that these regions are responsible for mediating the interactions with
Cby [8].
Upon titration of unlabelled CbyΔC20 to 15N-labelled TC-1 (2:1), decreases in
peak intensity were observed for residues within TC-1’s C-terminal half (Figure 3.8 B).
The peaks that displayed intensity losses matched the intensity losses observed when fulllength Cby was titrated to 15N-labelled TC-1 (Figure 3.8 A, C). A titration of the CbyC25
peptide, which comprises the C-terminal extension, to TC-1 did not result in any intensity
changes (Figure 3.9 A). Together, these results suggest that the C-terminal extension is
likely expendable for Cby’s interaction with TC-1.
Next, the individual halves of Cby, N-Cby and C-Cby, were titrated with 15Nlabelled TC-1. As expected, titrating N-Cby did not induce any changes in the HSQC
spectrum of TC-1 (Figure 3.9 B). Conversely, titrating C-Cby led to the broadening of
most TC-1 amide resonances (Figure 3.10 A, B). The drops in peak intensities were most
severe in the C-terminal half of TC-1, where many signals were broadened beyond
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detection. Additionally, titration of unlabelled TC-1 to 15N-labelled C-Cby led to the
appearance of a number of peaks (Figure 3.7).
The greater intensity losses observed in the TC-1 spectrum upon titration with CCby suggest that C-Cby binds TC-1 with a higher affinity than the full-length protein.
This was confirmed by ITC experiments, which revealed that C-Cby binds to TC-1 with a
Kd of ~ 2 µM (Figure 3.10 C, Figure 3.11 A). On the other hand, the interactions between
TC-1/full-length Cby and TC-1/CbyΔC20 are too weak to produce discernible enthalpy
changes with the protein concentrations (which are limited by the proteins’ solubilities)
used in the ITC experiments (Figure 3.11 B, C).
Intriguingly, when Coil-Cby was added to TC-1 in a 2:1 ratio, no changes in the
HSQC spectrum were observed (Figure 3.9 C). The lack of observed binding may be due
to its potential aggregation at the concentration (~100 µM) used for these NMR
experiments. Attempts to concentrate the protein to > 200 µM led to the observation of a
gel-like precipitate, again highlighting the importance of disordered regions for the
solubility of Cby.
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Figure 3.8 TC-1/Cby NMR titration experiments
A. Overlay of 1H-15N HSQC spectra of TC-1 in the absence (black) and presence (red) of
full-length Cby at a 1:2 ratio (TC-1 60 µM:Cby 120 µM). B. Overlay of 1H-15N HSQC
spectra of TC-1 in the absence (black) and presence (blue) of Cby∆C20 at a 1:2 ratio
(TC-1 60 µM:Cby∆C20 120 µM). C. Intensity ratios (I/Io) for assigned TC-1 amide
resonances in the presence (I) or absence (Io) of either full-length Cby or Cby∆C20.
Yellow shaded areas correspond to the three regions on TC-1 with high-helical
propensity as determined by chemical shift analysis [8].
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Figure 3.9 NMR titrations with TC-1/Cby constructs
A. Overlay of the 1H-15N HSQC spectra of TC-1 in the absence (black) and presence
(red) of N-Cby at a 1:2 ratio (TC-1:N-Cby). B. Overlay of the 1H-15N HSQC spectra of
TC-1 in the absence (black) and presence (red) of CbyC25 at a 1:2 ratio (TC-1:CbyC25).
C. Overlay of the 1H-15N HSQC spectra of TC-1 in the absence (black) and presence
(red) of Coil-Cby at a 1:2 ratio (TC-1:Coil-Cby).
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Figure 3.10 TC-1/C-Cby NMR and ITC binding experiments
A. Overlay of 1H-15N HSQC spectrum of TC-1 in the absence (black) and presence (blue)
of full-length C-Cby at a 1:2 ratio (TC-1 50 µM:C-Cby 100 µM). B. Intensity ratios (I/Io)
for assigned TC-1 amide resonances in the presence (I) or absence (Io) of either fulllength Cby (as shown in Figure 3.8) or C-Cby. Yellow shaded areas correspond to the
three regions on TC-1 with high-helical propensity as determined by chemical shift
analysis[8]. C. An ITC thermal profile of TC-1 binding to C-Cby. Thermodynamic
experimental values are displayed. Kd is the dissociation constant ΔH, ΔS and ΔG are the
change in enthalpy, entropy and Gibbs free energy upon binding at T = 298 K,
respectively.
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Figure 3.11 ITC thermograms for binding experiments between TC-1 and Cby
constructs
A. A duplicate ITC thermal profile of TC-1 binding to C-Cby in 10 mM ammonium
acetate. Thermodynamic experimental values are displayed. Kd is the dissociation
constant ΔH, ΔS and ΔG are the change in enthalpy, entropy and Gibb free energy upon
binding at T = 298.15 K, respectively. B. ITC thermal profile of TC-1 binding to fulllength Cby in 10 mM sodium acetate, pH 5.0. C. ITC thermal profile of TC-1 binding to
CbyΔC20 in 10 mM ammonium acetate, pH 5.0.
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3.4

Discussion

The mapping of coiled-coil domains using NMR spectroscopy has proven to be a
challenge for not only Cby, but also for other partially unstructured proteins such as
CHOP, Par-4 and NA14 [31,32,33]. For those three proteins, the only observable HSQC
peaks correspond to residues located in disordered regions. As demonstrated in this study,
HDX-MS is a valuable alternative technique for deciphering which residues make up
these coiled-coil domains.
Cby first exhibits HDX protection in large fragments comprised of residues 60-84
and 60-90. Our ability to set a defined boundary for the N-terminus of the coiled-coil is
limited by the size of the peptic fragments produced during online digestion. Meanwhile,
a peptic fragment comprising residues 85-90 displays further reduced HDX rates while
residues 91-98 display virtually no deuterium uptake over the course of the experiment.
These results align well with the predicted coiled-coil region, residues 68-102 [7].
The HDX data revealed a previously unrecognized structural feature, i.e.,
considerable disorder in the C-terminal extension of Cby (residues 102-126), where
deuterium levels around 90% were observed for the earliest time point of t = 1 min. This
behavior does not necessarily imply that the C-terminal extension is completely unfolded.
Instead, it is more likely that this region exhibits rapid coil/helix fluctuations. Following
the standard HDX model [46] one can estimate the average deuteration rate constant as
kHDX = Kop × kch, where Kop is the coil/helix equilibrium constant, and kch ≈ 7 min-1 is the
“chemical” exchange rate constant at pH 5. An assumed value of Kop = 0.3 corresponds to
a deuteration level of 90% for t = 1 min. Thus, our HDX data suggest that the residual
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helicity of the C-terminal extension could be as high as 77% (considering that a coil/helix
equilibrium constant of 23/77 yields Kop = 0.3). Although the C-terminal extension is not
part of the coiled-coil domain, it is not visible in the HSQC spectra of full-length Cby or
its C-terminal half (C-Cby). It is likely that the proximity of the C-terminal extension to
the coiled-coil and the suggested coil/helix fluctuations collectively contribute to signal
broadening of these residues.
Our NMR and CD spectroscopy experiments demonstrate that Cby’s C-terminal
extension is expendable for coiled-coil formation, in good agreement with a yeast twohybrid assay that demonstrated full-length Cby could bind to a large Cby fragment
(residues 60-112), where the C-terminal extension’s last 14 residues are not present [16].
However, the absence of the C-terminal extension results in a reduction in Cby’s
solubility. Importantly, this extension plays a major functional role as it contains Cby’s
nuclear localization signal, residues 123-126, which binds to importin-α [5].
From our NMR experiments, Cby’s coiled-coil domain mediates the interaction
with TC-1. For the Cby/TC-1 interaction, no binding was observed between TC-1 and the
CbyC25 peptide, while the CbyΔC20 construct was observed to bind TC-1 by NMR
spectroscopy. Notably, while the coiled-coil is required for the Cby/TC-1 complex
formation, we failed to detect interactions between Coil-Cby and TC-1 by NMR, possibly
due to the aggregation of the former at high concentration. Despite remaining α-helical as
shown by CD spectroscopy, the absence of both disordered ends on Coil-Cby drastically
reduces the solubility of this domain.
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The C-Cby construct bound to TC-1 with much greater affinity compared to fulllength Cby. Our ITC data, based on the calculated molar ratio, suggests that C-Cby binds
to TC-1 as a dimer. We speculate that the bound C-Cby dimer likely lies along the
helical region of TC-1’s C-terminal half. The difference in affinity for TC-1 between
full-length and C-Cby may be due to a higher entropic cost of binding for full-length Cby
compared to C-Cby. Alternatively, the disordered N-terminus of Cby may inhibit the
interaction by acting as an entropic bristle, that is, an unstructured region that impedes
surrounding macromolecules via random, thermally driven motions [47].
In summary, our HDX-MS data help characterize the structure and dynamics of
the NMR-invisible C-terminal half of Cby. The data reveal that Cby is comprised of a
disordered N-terminus, a short coiled-coil and an unstructured C-terminal extension.
These three structural elements were assessed for their importance to Cby’s interaction
with the Wnt signaling enhancer TC-1. Our results also provide insight into how Cby’s
disordered regions and coiled-coil work in concert to assemble higher order protein
complexes, such as the trimolecular Cby/14-3-3/β-catenin [6] or Cby/clusterin/NBPF1
complexes [15]. Cby’s N-terminus comprises the binding motifs for a number of binding
targets, including 14-3-3 protein and clusterin. In the free state, Cby’s N-terminus may
reduce the affinity for some binding targets that bind to its C-terminal half, as
demonstrated in this work with TC-1. However, this inhibition may be abrogated if the
N-terminus is present in a bound state. Such a mechanism may allow for cooperative,
sequential formation of multi-molecular Cby complexes.
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Chapter 4

4

Cby’s coiled-coil domain: Differing binding modes to
TC-1 and β-catenin

4.1 Introduction
The Wnt/β-catenin signaling pathway, activated by the Wnt family of cysteinerich glycoproteins, is critical in embryonic development, stem cell control and adult
tissue homeostasis [1,2,3]. Mutations to the Wnt genes as well as Wnt signaling
components are associated with various human diseases, including cancer [4,5].
Activation of the pathway occurs when the Wnt proteins interact with the cellular
receptors frizzled and lipoprotein receptor-related protein (LRP). Signaling is relayed
and transduced to the transcriptional co-activator β-catenin where it translocates to the
nucleus, interacts with the Tcf/Lef family of transcription factors and induces Wnt
signaling target genes [6]. When the pathway is turned off, cytosolic β-catenin exists
within a large protein complex, termed the destruction complex. This complex is
comprised of scaffolding proteins (Axin, APC) and a collection of kinases (GSK3β, Ck1)
that phosphorylate β-catenin [6]. Phosphorylated β-catenin is targeted for ubiquitination
and subsequent degradation through the proteasome [7].
With aberrant Wnt signaling being implicated in a number of diseases, cellular
regulation of the Wnt signaling cascade is vital. Regulation of the key player in the
pathway, β-catenin, is a focal point, with a number of its binding partners influencing its
phosphorylation, degradation, cellular localization and ability to interact with the Tcf/Lef
transcription factors [8,9,10]. One such modulator is the protein Chibby (Cby), an
antagonist of β-catenin-mediated signaling [11]. Cby’s antagonism is achieved using two
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mechanisms. First, it competes directly with the Tcf/Lef transcription factors for binding
to β-catenin [11] and secondly, in conjunction with the 14-3-3 proteins, promotes the
cytoplasmic sequestration of β-catenin [12,13]. These two modes of regulation
effectively suppress Wnt signaling [13].
Cby is regulated by a small, disordered protein named thyroid cancer-1 (TC-1)
[14]. The 106-residue TC-1 received its name when it was identified as a gene
overexpressed in papillary thyroid cancer [15]. By binding directly to Cby, TC-1
effectively frees β-catenin to bind to the Tcf/Lef factors and induces transcription of Wnt
genes [14].
Structurally, the 17.5 kDa Cby is partially disordered, comprising an intrinsically
disordered N-terminal half, while its C-terminus harbours a coiled-coil motif [16,17].
These two structural halves of Cby are independently responsible for interacting with the
protein’s Wnt signaling binding partners. The disordered N-terminal half comprises
Cby’s 14-3-3 binding motif and nuclear exportation signal [13], while the C-terminus
contains the binding sites for β-catenin [11] and TC-1 [14] as well as its nuclear
localization signal [13]. Cby interacts with the last α-helix on β-catenin (termed the helix
C) [18], whereas it binds to the C-terminal half of TC-1 [14,19].
The coiled-coil domain promotes the homo-dimerization of Cby and is predicted
to range from residues 73-102 [16], which is confirmed in our hydrogen-deuterium
exchange mass-spectrometry study discussed in Chapter 3. Some cell studies have
demonstrated the importance of Cby’s dimerization in Wnt signaling. By mutagenizing
some of the core leucines (L77, L84, L91, L98) within the coiled-coil region to alanine,
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Mofunanya et al. [16] demonstrated that Cby’s dimerization could be disrupted. These
engineered monomeric Cby mutants were incapable of binding to importin-α, the
receptor responsible for Cby’s nuclear localization. However, pull-downs showed that
monomeric Cby retained the ability to interact with β-catenin and TOPFLASH assays, a
reporter kit designed to monitor the activation of the Wnt signaling pathway in cultured
cells [20], showed that these mutants could still repress β-catenin-mediated signaling.
Conversely, although ITC experiments have shown that Cby interacts with TC-1 as a
dimer (Chapter 3), whether or not monomeric Cby can interact with TC-1 is unknown.
NMR spectroscopy represents a valuable technique in the characterization of
intrinsically disordered proteins [21,22]. However, analyzing the Cby/β-catenin
interaction using NMR spectroscopy is challenging due to Cby’s insolubility in buffers at
physiological pH, where β-catenin is most stable [17]. Moreover, the majority of
resonances in Cby’s C-terminal half are severely broadened out to disappearance as the
result of conformational exchange [17]. The large size of full-length β-catenin (88 kDa),
along with its elongated shape [18], leads to a rapidly decaying NMR signal, making
typical protein binding NMR experiments using labelled β-catenin unfeasible.
To further dissect Cby’s interaction between its coiled-coil domain and β-catenin,
a series of mutants were designed to either stabilize or destabilize the coiled-coil. The
goal of these mutants was to increase Cby’s solubility and to reduce the severe peak
broadening observed in Cby’s HSQC spectrum, enabling the Cby/β-catenin complex to
be studied using NMR spectroscopy. A diagram of Cby’s coiled-coil, represented as
helical wheels, is displayed in Figure 4.1. Within the four heptad-repeats of this domain,
there are four core leucines (L77, L84, L91, and L98) at position d and two asparagines
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(N81, N88) are buried in the core at position a. To destabilize the coiled-coil,
L84A/L98A (Cby-2A) and L77A/L84A/L91A/L98A (Cby-4A) mutants were generated.
Conversely, to stabilize the coiled-coil, the two asparagines in the hydrophobic core of
the domain, N81 and N88, were both mutated to leucine (Cby N81L/N88L). An
additional construct comprising six mutations (Cby-6mut,
N81L/N88L/L90R/L93R/I97R/L99E) was designed to strengthen the dimer interface
while removing the hydrophobic patch on the coiled-coil surface and to promote the
formation of an electrostatic bridge between residue E99 and K94.
Our findings demonstrate that the leucine to alanine mutants, Cby-2A and Cby4A, have additional peaks in their 1H-15N HSQC spectra compared to Cby-WT but
remain insoluble at pH ≥7. However, making these same mutations to recombinant
constructs comprising only the C-terminal half of Cby (C-Cby residues 67-126) lead to
drastically increased solubility as well as the appearance of the majority of NMR peaks.
Critically, these C-Cby mutants retain binding to β-catenin as demonstrated by pull-down
and NMR titration experiments.
These same mutants were tested for binding to TC-1. Our results demonstrate
that the destabilizing Cby-2A mutant was incapable of interacting with TC-1.
Additionally, although Cby N81L/N88L retained an interaction with TC-1, Cby-6mut did
not. Collectively, the results suggest Cby interacts with TC-1 as a dimer, with key
interacting residues present on the surface of the coiled-coil.
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Figure 4.1 Schematic of Cby's coiled-coil, represented as helical wheels
Core leucines (position d) are boxed, core asparagines at position a are highlighted in
purple, and surface-exposed hydrophobic residues are circled. Figure was taken from
Supplementary Material provided in the published manuscript by Mokhtazarda et al.
[17].
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4.2
4.2.1

Materials and Methods
Mutagenesis, Expression and Purification of Recombinant
Proteins

All Cby mutants were generated using the QuikChange Multi Site-Directed
Mutagenesis Kit (Agilent Technologies). Each mutant was confirmed through DNA
sequencing. Expression and purification of full-length Cby-WT, Cby-2A (L84A/L98A),
Cby-4A (L77A, L84A, L91A, L98A), Cby N81L/N88L and Cby-6mut (N81L, N88L,
L90R, L93R, I97R and L99E) were performed as previously described for Cby-WT [17].
Expression and purification of TC-1 was performed as described in [19]. The expression
and purification protocols for C-Cby-WT, N81L/N88L, 6mut and Coil-Cby-WT (residues
67-102) (which are expressed as His-MBP fusions) are described in Chapter 3. The CCby-2A and C-Cby-4A mutants were found to be soluble after TEV cleavage in a buffer
comprising 20 mM Tris, 50 mM NaCl, pH 7.5. C-Cby-2A and C-Cby-4A samples, were
concentrated and exchanged into 20 mM Tris, 50 mM NaCl, 3 M guanidine-HCl, pH 7.5
and run through a Superdex 200 column (GE Healthcare) in the same buffer comprising 6
M guanidine-HCl. Pooled protein fractions were dialyzed into 50 mM sodium phosphate,
pH 7.0.
The pET-28a expression vector for β-catenin, consisting of the first armadillo
repeat to the C-terminal end (residues 138-781) and termed β-catR1C, was generously
gifted from Dr. Wenqing Xu of the University of Washington [18]. The His-tagged
proteins were induced for over-expression in E. coli BL21 (DE3) cells, in M9 medium,
with 1 mM of IPTG upon reaching an O.D.600 of 0.7 at 37 °C. Cells were grown for 3
hours at 37 °C before harvesting. Cells were lysed and loaded onto Ni-NTA beads.
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Subsequent eluates were incubated with His-tagged TEV overnight at room temperature.
The cleavage mixture was then loaded onto Ni-NTA beads in 20 mM Tris, 50 mM NaCl
pH 7.5, with the His-tagged cleaved β-catR1C collected in the flow-through.
β-catR10C (tenth armadillo repeat to the C-terminus; residues 531-781) was
inserted for expression into a pDEST17 vector using Gateway Recombination Cloning
Technology (Thermo Fisher Scientific). The His-tagged β-catR10C was grown in E. coli
BL21 (DE3) pLysS cells at 37 °C in M9 medium. Upon reaching an O.D.600 of 0.7,
overexpression was induced with 1 mM of IPTG at 22 °C. Lysed cells were loaded onto
Ni-NTA beads and elutions were dialyzed into 50 mM sodium phosphate, pH 7.0. The
His-tag was not cleaved for solubility purposes.
All proteins used in this work were analyzed on SDS-PAGE and electrospray
ionization mass spectrometry for purity and to ensure they were the correct mass.

4.2.2

Circular Dichroism Spectropolarimetry
CD spectra and thermal melting curves were collected on a Jasco J-810

spectropolarimeter (Easton, MD). Spectra of full-length Cby-WT, Cby (N81L/N88L),
Cby-6mut, Cby-2A and Cby-4A and C-Cby(N81L/N88L), C-Cby-6mut (at
concentrations ranging from 0.15 mg/mL to 0.30 mg/mL) were collected in a 1 mm
cuvette at 25°C in 10 mM sodium acetate, pH 5.0 with 5 accumulated scans each.
Spectra for C-Cby-2A and C-Cby-4A were collected in 50 mM sodium phosphate, pH
7.0. The program CONTIN included in the DichroWeb online analysis software [23] was
used to deconvolute the CD spectra. Deconvolution was performed using the SMP180
(optimized for 190-240 nm) reference set [24,25].

121

For the melting curves of all Cby constructs, the temperature was scanned from
20 °C to 95 °C, with the ellipticity monitored at 222 nm. Full-length and C-terminal half
Cby-WT, Cby N81L/N88L and Cby-6mut were performed at a rate of 1 °C/min and fulllength Cby-2A and Cby-4A were performed at 3 °C/min.

4.2.3

Pull-down Assays
For the MBP-Cby fusion pull-down assays, 30 µg of His-MBP fusions (Coil-Cby,

C-Cby and all C-Cby mutants) in 500 µL were incubated with 30 µL of amylose resin for
1 hour in protein binding buffer (PBB) (20 mM Tris, 70 mM NaCl, pH 7.5) at room
temperature. After washing with two individual 500 µL washes with PBB, 100 µg of βcatR1C in 500 µL was incubated with the resin in PBB for 45 minutes at room
temperature. Beads were washed with 100 µL of PBB followed by an additional 75 µL
wash of PBB. Bound proteins were eluted with 50 µL of PBB containing 100 mM
maltose. 30 µL of the eluted fractions were run on SDS-PAGE.

4.2.4

NMR Spectroscopy
NMR experiments were performed on Varian Inova 600 MHz spectrometers

equipped with xyz-gradient triple resonance probe at 25 oC. Samples contained 10%
(v/v) D2O and sodium 2, 2-dimethyl-2-silapentane-5-sulfonate (DSS) was added as an
internal standard for chemical shift referencing. Buffers used for each experiment and
protein concentrations used for titration experiments are described within the figure
captions. NMR data were processed using NMRPipe [25] and analyzed using NMRView
[26].
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4.2.5

Peptide Synthesis
The Cby peptide comprising its C-terminal 25 residues (CbyC25) was purchased

from and synthesized at the Tufts University Core facility. The peptide was dissolved in
20 mM Tris, 50 mM NaCl, pH 7.5 for ITC experiments.

4.2.6

Isothermal Titration Calorimetry
Using a VP-ITC instrument (MicroCal), 0.6 mM of the CbyC25 peptide was

titrated from the syringe in 10 µL injections into the cell containing 20 µM β-catR1C.
The titration experiment was run in 20 mM Tris, 50 mM NaCl, pH 7.5 at 25 oC.
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4.3
4.3.1

Results
Design of Cby coiled-coil mutants and their effect on the
protein’s stability

CD spectra were collected for all mutants to assess their secondary structure
content and thermal denaturation experiments were used to measure their stability (Figure
4.2 A-D). The results for the deconvoluted spectra of all mutants are displayed in Table
4.1. The WT, N81L/N88L and Cby-6mut constructs share similar percentages of α-helix,
β-strand and turns-disorder secondary structures. Conversely, the Cby-2A and Cby-4A
mutants have a reduced level of α-helical content and an increased level of β-strand
content relative to Cby-WT.
Thermal melting curves were collected for each mutant using CD spectroscopy,
monitored at 222 nm (Figure 4.2 B, D). Cby-WT, as previously demonstrated in Chapter
3, displays a gradual loss in signal over the 20 °C – 60 °C temperature range followed by
a sharper loss of signal starting at approximately 60 °C, signifying the melting of the
coiled-coil. Cby-6mut follows a similar pattern as the WT in the 20 °C – 60 °C,
however, the continued loss of signal starting at 60 °C is much more gradual than the WT
protein, suggesting that the coiled-coil domain is more stable. Additionally, like the WT
protein, Cby-6mut is able to refold properly after its thermal denaturation (data not
shown). Interestingly, the N81L/N88L mutant showed almost no change in signal at 222
nm, suggesting its structure is extremely stable. Indeed, a CD spectrum of Cby
N81L/N88L taken at 80 °C shows a nearly identical curve to the protein at 25 °C (Figure
4.2 A, Table 4.1). As such, the L90R/L93R/I97R/L99E mutations in the Cby-6mut
construct, which also contains the N81L/N88L mutations, likely destabilize the coiled-
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coil of the Cby N81L/N88L mutant. Both the Cby-2A and 4A mutants, which lack a
coiled-coil structure, showed little reduction in CD signal over the course of the thermal
melt.
1

H-15N HSQC spectra of these Cby mutants were collected. The Cby

N81L/N88L and Cby-6mut spectra are very similar to that of Cby-WT (Figure 4.3 A, B),
indicating that only resonances derived from Cby’s N-terminus can be observed in these
mutants. HSQC spectra of Cby-2A and Cby-4A show an increase in the number of
observed peaks compared to Cby-WT (Figure 4.3 C). For the WT protein, ~ 61 amide
resonances of 149 non-proline residues (includes His-tag) are detected. Conversely, ~
101 resonances are observed in both Cby-2A and in Cby-4A. Despite the HSQCs of
Cby-2A and Cby-4A having more peaks, only 68% of the expected number of peaks are
observed, suggesting some self-association or conformational exchange may still be
occurring. As well, although these new observed resonances are all expected to originate
from Cby’s C-terminus, it is unknown if some residues have multiple peaks originating
from monomer and dimer species. While these two mutants display a similar number of
resonances, the Cby-2A mutant’s spectrum shows more peak crowding and line
broadening compared to the Cby-4A mutant where the peaks are sharper. The Cby-4A
mutant potentially shifts the monomer-dimer equilibrium more toward the monomeric
state than Cby-2A.
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Figure 4.2 CD spectra and thermal melts of full-length Cby coiled-coil mutants
A. CD spectra of full-length Cby-WT, N81L/N88L and Cby-6mut at 25 °C and Cby
N81L/N88L at 80 °C. Displayed spectra are the accumulation of 5 scans. B. Thermal
melting curves of full-length Cby-WT, N81L/N88L and Cby-6mut using CD at 222 nm.
C. CD spectra of full-length Cby-2A and Cby-4A. Displayed spectra are the
accumulation of 5 scans. D. Thermal melting curves of full-length Cby-2A and Cby-4A
using CD at 222 nm. All spectra collected in 10 mM sodium acetate, pH 5.0.
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Table 4.1 Deconvoluted CD spectra of full-length Cby and C-terminal Cby coiledcoil mutants
Unless otherwise specified, all spectra were collected at 25 °C
Full-length Cby
constructs

C-Cby constructs

Helix
26%

Strand
24%

Turns/Disorder
50%

N81L/N88L
N81L/N88L at 80
°C
6mut
2A
4A

29%
32%

17%
10%

54%
58%

24%
12%
17%

26%
32%
31%

50%
56%
52%

N81L/N88L
6mut
2A
4A

60%
50%
8%
18%

3%
7%
36%
24%

37%
43%
56%
58%

WT
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Figure 4.3 1H-15N HSQC NMR spectra of full-length Cby-WT and coiled-coil
mutants
A. Cby N81L/N88L (blue) overlayed with WT (black). B. Cby-6mut (red) overlayed with
WT (black). C. Cby-2A (green) overlayed with Cby-4A (orange). All spectra were
collected in 10 mM sodium acetate buffer, pH 5.0.
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4.3.2

Interactions between TC-1 and Cby mutants
In Chapter 3, our ITC data suggested that TC-1 bound to dimeric Cby, however it

is still unclear whether TC-1 can bind to monomeric Cby and which specific residues on
Cby’s coiled-coil mediate the interaction. Here we used NMR to investigate the
interactions of TC-1 with the Cby-2A, Cby-6mut and Cby N81L/N88L mutants.
Decreases in peak intensities were observed predominantly in TC-1’s C-terminal
half upon titration of unlabelled Cby N81L/N88L to 15N-labelled TC-1 (2:1) (Figure 4.4
A, B), similar to what has previously been observed in WT Cby titrations [19]. In
contrast, titration of Cby-6mut to TC-1 did not lead to any substantial decreases in peak
intensity (Figure 4.4 C, D). Collectively, the data demonstrates that although TC-1
maintained an interaction with the coiled-coil stabilized N81L/N88L mutant, the
hydrophobic patch on the surface of the coiled-coil, which is mutated in Cby-6mut, may
mediate Cby’s interaction with TC-1. However, individual or a combination of mutations
to residues in this hydrophobic patch (such as L90R, L93R, I97R, without N81 or N88
mutations) should be designed and tested to confirm their significance in TC-1 complex
formation. Next, titration of Cby-2A to TC-1 did not produce any significant changes in
peak intensities, suggesting that monomeric Cby is unable to bind to TC-1 (Figure 4.4 E,
F).
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Figure 4.4 NMR titrations with TC-1 and Cby coiled-coil mutants
A. Overlay of 1H-15N HSQC spectra of TC-1 in the absence (black) and presence (blue)
of Cby N81L/N88L at a 1:2 ratio (TC-1 60 µM: Cby 120 µM). B. Intensity ratios (I/Io)
for assigned TC-1 amide resonances in the presence (I) and absence (Io) of Cby
N81L/N88L. C. Overlay of HSQC spectra of TC-1 in the absence (black) and presence
(red) of Cby 6mut at a 1:2 ratio (TC-1 35 µM: Cby 70 µM). D. I/Io values for assigned
TC-1 amide resonances in the presence (I) and absence (Io) of Cby-6mut. E. Overlay of
HSQC spectra of TC-1 in the absence (black) and presence (green) of Cby-2A at a 1:2
ratio (TC-1 60 µM: Cby 120 µM). F. I/Io values for assigned TC-1 amide resonances in
the presence (I) and absence (Io) of Cby-2A. All spectra collected in 10 mM sodium
acetate buffer, 50 mM NaCl, pH 5.0.
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4.3.3

Structural analysis and stability of mutations to the coiled-coil
of Cby in constructs lacking the disordered N-terminus
Characterizing the interaction between Cby and β-catenin using NMR

spectroscopy is hindered by the two proteins’ buffer incompatibility and by the peak
broadening observed in Cby’s C-terminal half. While more resonances are observed in
the Cby-2A and 4A mutants’ HSQCs, all coiled-coil mutations to full-length Cby
discussed above are only soluble in buffers of low pH (pH 5) and ionic strength, while
nearly full-length β-catenin (βcatR1C) is stable in buffers closer to pH 8 with 50-100 mM
NaCl. Therefore, we sought to design the same set of mutations on a construct
comprising the C-terminal half of Cby (C-Cby, residues 67-126), to see if the removal of
Cby’s disordered N-terminus may help stabilize these mutant proteins in a buffer
compatible with β-catenin.
Like the full-length protein, CD spectra and thermal melting curves were
collected for each C-Cby mutant (Figure 4.5, Table 4.1). As expected, the C-Cby
N81L/N88L and 6mut mutants remain folded, containing much higher fractional αhelical content compared to the full-length mutants in 10 mM sodium acetate, pH 5.
Additionally, the thermal melting profiles for these two mutants, measured at 222 nm,
show very similar curves to what was observed in the full-length mutants. C-Cby
N81L/N88L displayed very little reduction in signal over the course of the melt.
Conversely, C-Cby-6mut showed a gradual reduction in signal from 20-65 °C, followed
by a secondary phase of melting from 70-95 °C. Although C-Cby-6mut appears to be
less thermally stable than C-Cby N81L/N88L, it is still remarkably more stable than what
was observed for C-Cby-WT (see Chapter 3, Figure 3.5 D).
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The C-Cby-2A and 4A mutants were found to be soluble in sodium phosphate
buffer, pH 7 upon their refolding (as outlined in the Materials and Methods section). CD
spectra of the C-Cby-2A and 4A mutants in 50 mM sodium phosphate, pH 7 show
drastically reduced α-helical content and increased β-strand content, confirming the
coiled-coil has been disrupted (Figure 4.5, Table 4.1).
The HSQCs of all C-Cby mutants were collected to determine whether they
suffered the same severe line broadening as the C-Cby-WT (see Chapter 3, Figure 3.7).
The C-Cby N81L/N88L and C-Cby-6mut HSQCs (Figure 4.6, A, B) show multiple weak
and heavily crowded/clustered peaks characteristic of an oligomerized or aggregated
protein. In contrast, the C-Cby-2A and 4A HSQCs, recorded in 50 mM sodium
phosphate, pH 7, have sharp, dispersed peaks (Figure 4.6, C, D). Peak detection on the
C-Cby-2A spectra counts ~ 50 resonances out of the 60 non-proline residues while CCby-4A has ~ 51 of 60 expected peaks. Similar to what was observed between the fulllength Cby-2A and 4A HSQC spectra, C-Cby-4A has slightly sharper and less crowded
peaks than C-Cby-2A.
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Figure 4.5 CD spectra and thermal melts of C-Cby coiled-coil mutants
A. CD spectra of C-Cby N81L/N88L and 6mut collected in 10 mM Na acetate, pH 5.0.
Displayed spectra are the accumulation of 5 scans. B. Thermal melting curves of C-Cby
N81L/N88L and C-Cby 6mut using CD at 222 nm, collected in 10 mM Na acetate, pH
5.0. C. CD spectra of C-Cby 2A and 4A collected in 50 mM sodium phosphate, pH 7.0.
Displayed spectra are the accumulation of 5 scans.
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Figure 4.6 1H-15N HSQC NMR spectra of C-Cby WT and C-Cby coiled-coil mutants
A. C-Cby N81L/N88L. B. C-Cby-6mut. C. C-Cby-2A. D. C-Cby-4A. C-Cby
N81L/N88L and 6mut were collected in 10 mM sodium acetate, pH 5.0 and C-Cby-2A
and 4A were collected in 50 mM sodium phosphate, pH 7.0.
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4.3.4

Cby’s Interaction with β-catenin
Previous work has demonstrated the C-terminal half of Cby alone can bind to β-

catenin [11]. Our hydrogen-deuterium exchange (HDX) mass spectrometry results,
discussed in Chapter 3, revealed that Cby’s C-terminal half contains the coiled-coil
region and a disordered C-terminal extension ranging from residues 101-126. We
investigated whether or not the coiled-coil region of Cby is sufficient for binding βcatenin. A pull-down experiment using amylose resin reveals that an MBP-fused Cby
construct comprising Cby’s coiled-coil domain (Coil-Cby, residues 67-104) retains the
ability to bind β-catR1C, while MBP alone does not (Figure 4.7, A). Additionally,
isothermal titration calorimetry (ITC) reveals that a synthetic peptide comprising Cby
residues 102-126 shows no binding to β-catR1C (Figure 4.7, B). However, this ITC
result does not rule out very weak binding between the C-terminal extension and βcatenin. Alternatively, the C-terminal extension may only participate in the interaction in
the context of the full-length protein.
Next, we tested whether the C-Cby coiled-coil mutants could interact with βcatR1C using an MBP pull-down assay. Full-length Cby-2A and 4A have already been
shown to bind to β-catenin using a similar assay using MBP-fusion Cby proteins [16].
Results of the assay confirm this, as C-Cby-2A pulled-down β-catR1C, while the C-Cby
N81L/N88L and C-Cby-6mut mutations compromised Cby’s interaction with β-catR1C
(Figure 4.7, C).
With the C-Cby-2A construct able to bind to β-catR1C, along with it being
soluble at physiological pH and having observable amide resonances in its 1H-15N HSQC
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spectrum, we were able to test the binding of these two proteins using NMR
spectroscopy. Titration of β-catR1C to C-Cby-2A at a 0.3:1 ratio showed peak intensity
loss for some residues, confirming the binding result of the pull-down assay (Figure 4.8).
Using NMR spectroscopy to assess the binding between β-catenin and C-Cby-2A
from β-catenin’s perspective is challenging due to the large size of β-catR1C (~ 70 kDa).
Therefore, as initial work, we attempted to use a smaller β-catenin construct comprising
armadillo repeat 10 to the C-terminus (β-catR10C, 28 kDa), which still contains Cby’s
proposed binding site, helix C on β-catenin [18]. Unfortunately, the HSQC of β-catR10C
displays less than half of the expected number of amide resonances expected, many of
which are weak, crowded and dispersed over a narrow 1H chemical shift range (Figure
4.9, A). In a previous study, NMR titration experiments by Xing et al. [18] were
designed to assess whether the disordered C-terminal end of β-catenin interacted with βcatenin’s armadillo repeats or disordered N-terminal tail. To do so, they expressed and
purified the 15N-labelled C-terminal tail (residues, 697-781) of β-catenin and titrated an
unlabelled construct comprising the armadillo repeats (1-686) (Figure 4.9, B). The
group’s collected HSQC spectrum of the C-terminal tail looks extremely similar to what
we observe in the β-catR10C spectrum, suggesting that no resonances from the armadillo
repeats in β-catR10C are observed. Importantly, a CD spectrum of β-catR10C
demonstrates the protein is folded (deconvolution of spectrum: 33% α-helix, 21% βstrand, 46% turns/disordered) (Figure 4.9, C). An even smaller β-catenin construct,
perhaps with a truncated C-terminal tail, may be required to assess the complex from βcatenin’s perspective.
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Figure 4.7 Cby binding to β-catenin using pull-down assays and ITC
A. Binding of Cby constructs (C-Cby, Coil-Cby) evaluated by an in vitro pull-down
assay. B. ITC profile of the CCby25 peptide titrated to β-catR1C. C. Binding of C-CbyWT and mutants evaluated by an in vitro pull-down assay.
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Figure 4.8 NMR titration experiment with C-Cby-2A and β-catenin
On left: 1H-15N HQSC of C-Cby 2A (black) overlayed with C-Cby 2A in the presence of
β-catR1C (red) at a 1:0.3 molar ratio (C-Cby 2A: β-catR1C, 45 µM: 15 µM. On right:
Zoomed in segment that is boxed in on the left spectrum. Arrows point to peaks with
greatest losses in intensity.
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Figure 4.9 Characterization of β-catR10C
1
H-15N HSQC spectrum of His-tagged β-catR10C in 50 mM sodium phosphate, pH 7.0.
B. 1H-15N HSQC spectrum of C-terminal β-catenin (residues 687-781) in 20 mM Tris,
100 mM NaCl, 2mM DTT, pH 7.5 collected and reported by Xing et al. [18]. C. CD
spectrum (5 accumulated scans) of His-tagged β-catR10C in 50 mM sodium phosphate,
pH 7.0.
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4.4

Discussion

Attempts to analyze the structural mechanisms by which Cby achieves its
antagonistic role in the Wnt signaling pathway remain hindered by the protein’s
insolubility. Additionally, characterizing the protein using NMR spectroscopy is
hampered by the invisibility of peaks in its C-terminal half, likely due to conformational
exchange [17]. In this work, we have attempted to use two mutagenesis strategies to
generate recombinant Cby that is soluble in buffers closer to physiological pH, and that
may promote the appearance of C-terminal peaks in 1H-15N HSQC spectra. The first
strategy was to stabilize the coiled-coil through mutation of core asparagines (Cby
N81L/N88L), followed by the removal of hydrophobic residues on the surface of the
coiled-coil (Cby-6mut, N81L/N88L/L90R/L93R/I97R/L99E). While both of these
mutants led to a more stabilized coiled-coil relative to WT, both proteins remained
insoluble at physiological pH and did not produce additional peaks in their HSQC
spectra. The second strategy involved breaking the coiled-coil domain using core leucine
to alanine mutations that have previously been found to produce monomeric Cby. While
these Cby-2A (L84A/L98A) and 4A (L77A/L84A/L91A/L98A) mutants successfully
disturbed the coiled-coil and produced additional resonances in their HSQC spectra, they
remained highly insoluble. However, by utilizing the same 2A and 4A mutations to the
C-terminal half of Cby (C-Cby), we obtained a soluble Cby construct that could be used
to study the Cby/β-catenin complex using NMR spectroscopy.
While TC-1 and β-catenin both interact with Cby’s coiled-coil domain [11,14],
their modes of interaction may be different. With TC-1, it appears to preferentially bind
to dimeric Cby as it fails to interact with the monomeric mutant, Cby-2A. In order to
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bind to dimeric Cby, TC-1 would have to interact with the surface of the coiled-coil.
Indeed, while TC-1 maintained an interaction with the N81L/N88L Cby mutant, this
binding was abolished with Cby-6mut, which has three hydrophobic residues on the
surface of the coiled-coil mutated to arginine (L90R, L93R, I97R). Critically, the design
of Cby mutants with mutations to solely L90, L93 and/or I97R (no mutations to the core
asparagines, N81L/N88L) should be made to confirm their importance in the TC-1
interaction. Conversely, β-catenin was able to bind to monomeric C-Cby-2A as
demonstrated in a pull-down assay and NMR titration experiment, but was unable to
interact with C-Cby N81L/N88L and C-Cby-6mut in our pull-down assay.
The differing modes of interaction in the Cby/TC-1 and Cby/β-catenin complexes
may be critical to Cby’s regulation in Wnt signaling. If β-catenin exclusively binds to
monomeric Cby, then TC-1 will not only antagonize Cby by competing with β-catenin
for binding to Cby’s C-terminal half, but may also keep Cby in a dimeric state.
Of note, it is important to point out that being restricted to utilizing pull-down
assays to characterize the Cby/β-catenin complex is the result of the severe insolubility of
Cby, hindering our ability to quantitatively assess the strength of the interactions between
these Cby mutants and β-catenin. While β-catenin can bind to monomeric Cby, it’s of
interest to determine whether it binds to the surface exposed residues of Cby’s coiled-coil
or its core residues. Also, it is unknown if Cby’s C-terminal extension plays a role in the
interaction. Our NMR titration experiment using 15N-labelled C-Cby-2A and unlabelled
β-catR1C showed reduced peak intensities for a number of residues. Backbone chemical
shift assignment of the 1H-15N HSQC spectrum of C-Cby-2A will be critical to determine
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which residues undergo peak intensity loss and may help in identifying the residues that
specifically bind to β-catR1C. Notably, our purification yields only ~ 0.4 mg per L of
growth in M9 medium, therefore a large scale growth will be required to obtain a
sufficiently high concentration for 3D NMR experiments.
Although C-Cby-2A can help provide molecular details of the Cby/β-catenin
complex, it is unfortunate that the full-length Cby-2A remains insoluble, as the role of
Cby’s N-terminus in the interaction, if any, cannot be determined. Although the Nterminal half of Cby cannot bind to β-catenin on its own, it may still form subsequent
secondary contacts with β-catenin after the C-terminal half of Cby interacts. Such a
mechanism is observed in another inhibitor of β-catenin called ICAT (inhibitor of βcatenin and Tcf4) [27,28]. ICAT consists of an α-helical N-terminal half and a
disordered C-terminal half. ICAT’s antagonism is achieved when its N-terminal helical
bundle anchors itself into armadillo repeat 12, followed by its unstructured C-terminal
half interacting around repeats 5-9. ICAT’s C-terminal half cannot bind to β-catenin
alone, however, and its N-terminal helical half, although able to bind on its own, cannot
inhibit Tcf4 binding [29]. As such, the N-terminal half of ICAT must first anchor to βcatenin, enabling its C-terminal half to subsequently bind and mask the Tcf4 binding site
(armadillo repeats 2-10). Seeing as Cby’s C-terminal half anchors to the helix C (and
possibly armadillo repeat 12) of β-catenin, it is possible Cby’s unstructured N-terminus is
utilized to mask the Tcf4 binding site.
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Chapter 5

5

Summary and Perspectives
The Wnt signaling antagonist Chibby (Cby) acts on the transcriptional co-

activator β-catenin, preventing its interaction with the Tcf/Lef transcription factors and in
concert with the 14-3-3 proteins, promotes β-catenin’s cytoplasmic sequestration [1,2].
The structural mechanisms by which Cby interacts with the Wnt signalling components
14-3-3 and β-catenin remain elusive, largely due to recombinant Cby’s insolubility, as
well as its partially disordered structure. Cby harbours a coiled-coil domain in its Cterminal half while its N-terminal half is unstructured. These individual halves of Cby
contain binding motifs for the Wnt signalling components 14-3-3, β-catenin and the Cby
antagonist, TC-1. Cby’s N-terminal half contains a 14-3-3 binding motif, whereas its Cterminal half is responsible for binding to β-catenin and TC-1.
Cby has proven to be a challenge to work with using NMR spectroscopy, a
valuable and powerful tool in the analysis of disordered proteins. In addition to Cby
requiring low pH (~ 5) and ionic strength to remain soluble, residues within in its Cterminal half experience severe line broadening in the protein’s 1H-15N HSQC spectra
[3]. This line-broadening, likely due to conformational exchange of Cby’s coiled-coil,
not only hinders characterizing Cby by itself, but also the analysis of its protein-protein
interactions. Despite these challenges, the work in this thesis provides molecular insights
into the protein’s interactions with the Wnt signalling components 14-3-3, β-catenin and
TC-1.
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5.1 Characterizing the Cby/14-3-3 Interaction
Upon phosphorylation by the kinase Akt, Cby forms a complex with 14-3-3 to
facilitate the nuclear export of β-catenin, thereby suppressing Wnt signalling [3]. Using a
combination of X-ray crystallography, NMR spectroscopy and isothermal titration
calorimetry, the molecular details of the Cby/14-3-3ζ interaction were revealed. Using a
synthetic phosphorylated Cby peptide comprising Cby’s 14-3-3 binding motif, the crystal
structure of the 14-3-3ζ/phosphorylated Cby complex was solved. In addition to the
canonical 14-3-3 binding mode observed in the solved crystal structure, NMR
spectroscopy and ITC experiments showed that residues flanking Cby’s 14-3-3 binding
motif are important to the interaction. First, ITC experiments using phosphorylated Cby
peptides of different lengths demonstrated that flanking residues contribute to the binding
affinity. Second, upon completion of the backbone resonance assignment of 14-3-3ζ,
NMR titration experiments revealed that residues outside of 14-3-3’s conserved binding
cleft, namely a flexible loop consisting of residues 203-210, are involved in the Cby
interaction. While the structural characterization of the complex focused on the ζ
isoform of 14-3-3, ITC experiments showed that Cby binds to all seven 14-3-3 human
isoforms.
The vast majority of 14-3-3 complexes solved by X-ray crystallography are
limited to using phosphorylated peptides. While this may be due to the technical
challenges of crystallizing protein-protein complexes, the majority of 14-3-3 binding
partners are thought to be partially disordered [4] and may therefore be noncrystallizable. To date, there is only one structure of a nearly full-length binding partner
(Serotonin N-acetyltransferase or AANAT) in complex with 14-3-3 [5]. The
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AANAT/14-3-3 complex structure reveals secondary binding contacts (contacts outside
of the 14-3-3 binding groove, and outside of the binding partner’s 14-3-3 binding motif)
between AANAT and 14-3-3. Similar to what was observed in the 14-3-3/Cby complex,
other structural studies looking at 14-3-3 binding partners, such as integrin [6], have
demonstrated that residues flanking their 14-3-3 binding motifs contribute to their
interactions with 14-3-3. Our completion of the 14-3-3ζ backbone assignment may aid in
unveiling secondary contacts between 14-3-3 and binding partners that lack discernible
electron density due to their dynamics in their co-crystallized structures, or for complexes
that are extremely challenging to crystallize.

5.2 Elucidating the structural elements of Cby and their
interplay in target recognition
Previous structural analyses of Cby using NMR spectroscopy suffered from
severe line broadening within the protein’s C-terminal half, hindering the characterization
of its coiled-coil domain. In our study described in Chapter 3, we used hydrogendeuterium exchange mass spectrometry (HDX-MS) as a complementary technique to
examine the structural properties of Cby. Our results reveal three individual structural
elements on Cby, its disordered N-terminus, the coiled-coil domain and a C-terminal
unstructured extension consisting of the last ~ 25 residues. A series of truncation
constructs were designed to assess the roles each structural element plays in the overall
stability of Cby as well as their role in binding to the Cby antagonist TC-1. CD and
NMR data showed that Cby maintains a coiled-coil structure upon deletion of either
disordered region. Additionally, NMR and ITC binding experiments demonstrate that the
Cby and TC-1 interaction is retained upon deletion of either the N-terminal half or C-
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terminal extension, highlighting that the coiled-coil domain is vital to complex formation.
Moreover, Cby appears to bind to TC-1 as a dimer. Interestingly, the C-terminal half of
Cby alone binds to TC-1 with significantly greater affinity compared to the full-length
protein. Our results suggest that Cby’s flanking disordered regions affect the stability of
the coiled-coil domain and its ability to target binding partners, potentially due to a
higher entropic cost of binding.

5.3 Differing binding modes for the Cby/TC-1 and Cby/βcatenin complexes
A study by Mofunanya et al. [7] demonstrated that alanine substitutions to two or
more of the four critical leucines within Cby’s core of its coiled-coil domain (L77, L84,
L91, L98) were sufficient for eliminating the dimerization of Cby. Moreover, these Cby
mutants retained the ability to interact with β-catenin and repress β-catenin-mediated Wnt
signalling. Our work described in Chapter 4 focused on determining whether these Cby
mutants could be utilized to study the Cby/β-catenin complex using NMR spectroscopy,
with the expectation that the disrupted coiled-coil may improve the solubility of Cby and
lead to the appearance of C-terminal residue peaks in the protein’s C-terminal half. Our
findings show that two Cby mutants with alanine substitutions (L84A/L98A, or 2A, and
L77A/L84A/L91A/L98A, or 4A) disrupt the coiled-coil in the full-length Cby, but
remain highly insoluble in buffers close to physiological pH. However, when the same
mutations were made to a Cby construct comprising its C-terminal half alone (C-Cby,
residues 67-126), the mutants were found to be soluble at physiological pH.
Additionally, the majority of peaks are visible in the C-Cby 2A and 4A 1H-15N HSQC.
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An NMR titration experiment found that the C-Cby 2A construct binds to β-catenin as
evidenced by drops in peak intensity for some resonances.
Additional mutants were designed along Cby’s coiled-coil and tested for binding
to TC-1. It was found that mutating surface exposed hydrophobic residues to arginines
effectively abolished Cby’s interaction with TC-1. With Cby binding to TC-1 as a dimer,
it is reasonable to assume residues on the surface of the coiled-coil would mediate the
interaction with TC-1.

5.4
5.4.1

Future Directions and Perspectives
Characterizing the 14-3-3/Cby interaction in the context of
full-length Cby

The Cby/14-3-3 interaction has been extensively studied using synthetic
phosphorylated Cby peptides. However, questions remain as to how the complex is
formed when full-length Cby is bound. First, as the 14-3-3 dimer is able to bind to two
Cby molecules at the same time, it is of interest to find out if two bound Cby proteins
could still form a coiled-coil when bound to 14-3-3. The mechanisms for protein
interactions involving unstructured proteins has largely fallen under a now out-dated
paradigm of disorder-to-order transitions, as a growing amount of evidence reveals that
disordered proteins may remain highly dynamic or “fuzzy” in their bound states [8].
Thus, although the C-terminal ends of each Cby molecule exit the 14-3-3 binding cleft at
opposing ends of the 14-3-3 dimer, there could be sufficient length and flexibility in
Cby’s unstructured N-terminus for the coiled-coil to still form. Determining the
particular binding orientation and stoichiometry necessary for the Cby/14-3-3 interaction
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is critical towards the understanding of Cby-mediated β-catenin cytoplasmic
sequestration.
Several obstacles must be overcome to study this interaction. First, the in vitro
phosphorylation of Cby by the kinase Akt must be done in an Akt-active buffer, and one
which will not cause Cby to aggregate. As such, successful phosphorylation may require
an MBP or GST fusion Cby protein. Alternatively, a recently developed methodology
allows the incorporation of phosphoserine into proteins in vivo in E. coli [9]. This
powerful new tool was established by engineering the translational machinery in bacteria
to enable phosphoserine to be integrated into proteins. This developing method has
effectively been used to over-express several phosphorylated proteins [9,10,11]. The
second major hurdle will be finding a compatible buffer for 14-3-3 and phosphorylated
Cby.

5.4.2

Cby’s Disordered Ends Modulate Target Binding and
Applicability of HDX-MS to Other Protein Studies
An intriguing result from our NMR and isothermal titration calorimetry

experiments in Chapter 3 showed that the C-terminal half of Cby bound to TC-1 with
significantly greater affinity than the full-length protein. This suggest that the free
unstructured N-terminal domain may auto-inhibit (potentially as an entropic bristle [12])
Cby’s binding targets from interacting with the coiled-coil domain. This begs the
question that if Cby’s N-terminus is already bound to a protein, for example 14-3-3,
whether this auto-inhibition may be relieved, allowing the C-terminus to bind to client
proteins with high affinity. This mechanism would allow for sequential binding events,
and would demonstrate cooperativity between Cby’s structural halves.
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As demonstrated in our HDX-MS experiment on Cby, this technique may be useful in
characterizing and mapping of coiled-coil domains in other partially disordered proteins.
Like Cby, NMR studies involving the coiled-coil containing proteins CHOP [13], Par-4
[14] and NA14 [15] have been troubled by line broadening for residues within their
coiled-coils. HDX-MS can provide details on the size and dynamics of their respective
coiled-coil domains.

5.4.3

Monomeric Cby and its interaction with β-catenin
As C-Cby 2A is soluble and its peaks are present in the protein’s HSQC spectrum,

backbone assignment of this construct, followed by titration experiments may help in
deciphering which residues within the coiled-coil are responsible for binding to β-catenin.
Despite the challenges in characterizing the β-catenin/Cby interaction, it has been
speculated that Cby may antagonize β-catenin in a similar fashion to ICAT [16]. In the
bound state, an α-helical bundle located in ICAT’s N-terminus anchors within armadillo
repeats R10-R12 of β-catenin and likely interacts with helix C on β-catenin as well
[16,17,18]. ICAT’s disordered N-terminus then wraps around armadillo repeats R5-R9.
The disordered C-terminus is responsible for displacing the Tcf/Lef transcription factors
whose binding sites extend along repeats R2-R10 [17,19]. This mode of action has been
referred to as an “anchor-and-kick” mechanism [16]. Intriguingly, despite the disordered
C-terminal domain of ICAT burying 1700 Å of surface into β-catenin, and forming
similar contacts in repeats R5-R9 as those seen in APC, Tcf and Lef, it is unable to
interact with β-catenin in the absence of the N-terminal helical bundle [19]. Moreover,
while the N-terminal α-helical bundle of ICAT alone maintains binding to β-catenin, it is
incapable of displacing the Tcf/Lef transcription factors [17]. With regards to the β-
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catenin/Cby interaction, Cby’s C-terminal coiled-coil domain is responsible for binding
to the helix C of β-catenin and can bind independently of its N-terminal half.
Conversely, its disordered N-terminus does not bind to β-catenin alone.
While ICAT and Cby may share similar modes of antagonism, Cby’s dimerization
represents an additional layer of complexity. Mutations to monomerize Cby retain the
ability to bind to β-catenin, however whether Cby can interact in a dimeric state and what
effect this may have on its effectiveness as a Wnt signaling antagonist must still be
elucidated.

5.5

Conclusion

The coexistence of intrinsic disorder and coiled-coil domains is found throughout the
proteome. Elucidating the structural mechanisms by which Cby interacts with itself, βcatenin, 14-3-3 and TC-1 not only provides insight into its role as an antagonist in the
Wnt signalling pathway, but offers increased understanding of how dual-module proteins
consisting of intrinsic disorder and coiled-coil domains function as hubs in signalling
cascades linked to human disease.
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